Compositions, methods of using same, and kits comprising same

Abstract

The present disclosure relates to compositions, nutraceutical compositions, and dietary supplements that improve gut health, enhance energy, improve focus and energy, reduce cravings, improve stress management, improve overall health, promote healthy aging, replenish nutrients, support immune health, promote healthy skin, promote hair and nail growth, and enhance recovery after physical activity. The compositions comprise one or more of each of seaweeds, enzymes, and protein; two or more of each of adaptogens, botanicals, extracts, fibers, microalgae, micronutrients, minerals, vitamins, and whole fruit or vegetable powders; and three or more probiotics.

Description

[0001] COMPOSITIONS, METHODS OF USING SAME, AND KITS COMPRISING SAME

[0002] 1. BACKGROUND

[0003] Nutrition supplements are well known and have been commercially available for many years. Nutrition supplements are designed to supplement the diet with nutrients that may be lacking or insufficiently provided by food alone. These supplements come in different forms, including tablets, capsules, powders, liquids, and gummies and provide a wide range of vitamins, minerals, herbs, and other substances. Nutrition supplements can be taken in addition to a regular diet, as a meal replacement, or in lieu of food.

[0004] One such nutrient supplement is AG1® by Athletic Greens. ('W’c'rc here to help you feel healthy,” available on the World Wide Web at drinkagl .com.) While traditional multivitamin and mineral supplements generally come in tablet form, AG1® comes in powder form. AG1® (which is the 52nditeration) contains a combination of 75 vitamins, minerals, phytonutrients, wholefood nutrients, probiotics, prebiotics, digestive enzymes, stress adaptogens, functional mushrooms, and superfoods. AG1® has been shown in a set of in vitro studies simulating the human gastrointestinal tract to support a healthy gut. In a single arm study that assessed the self-perceived efficacy of AG1, participants reported feeling positive impacts on stress, digestion, and energy. Additionally, a double-blind randomized placebo-controlled trial in 30 participants over 28 days showed AG1 doubled the levels of healthy bacteria including L. acidophilus and B. bifidum in the gut.

[0005] Despite the effectiveness of AG1® (iteration 52), there is still a need to provide improved nutrition compositions and methods for improving gut health, for enhancing energy, for improving focus, for reducing cravings, for improving stress management, for improving health, for promoting healthy aging, for replenishing nutrients, for supporting immune health, for promoting skin health, for promoting hair and nail growth, and for enhancing recovery after physical activity.

[0006] Citation of any reference in this section is not to be construed as an admission that such reference is prior art to the present disclosure.

[0007] 2. SUMMARY OF THE DISCLOSURE

[0008] The present disclosure relates to compositions, nutraceutical compositions, and dietary supplements that improve gut health, enhance energy, improve focus and energy, reduce cravings, improve stress management, improve overall health, promote healthy aging, replenish nutrients, support immune health, promote healthy skin, promote hair and nail growth, and enhance recovery after physical activity. The compositions comprise one or more of each of seaweeds, enzymes, and protein; two or more of each of adaptogens, botanicals, extracts, fibers, microalgae, micronutrients, minerals, vitamins, and whole fruit or vegetable powders; and three or more probiotics.

[0009] In a particular embodiment, the composition comprises one or more of each of seaweeds, enzymes, and protein; two or more of each of adaptogens, botanicals, extracts, fibers, microalgae, micronutrients, minerals, vitamins, and whole fruit or vegetable powders; and three or more probiotics.

[0010] In a particular embodiment, the composition comprises one or more of each of seaweeds, enzymes, and proteins; two or more of microalgae; and three or more of each of probiotics, adaptogens, botanicals, extracts, fibers, micronutrients, minerals, vitamins, and whole fruit or vegetable powders.

[0011] In a particular embodiment, the composition comprises one or more of each of seaweeds, enzymes, and proteins; two or more of microalgae; three or more probiotics and fibers; and four or more of each of adaptogens, botanicals, extracts, micronutrients, minerals, vitamins, and whole fruit or vegetable powders.

[0012] In a particular embodiment, the composition comprises one or more of each of seaweeds, enzymes, and protein; two or more of microalgae; three or more of each of probiotics and fibers; four or more of each of botanicals, micronutrients, and whole fruit or vegetable powders; and five or more of each of adaptogens, extracts, minerals, and vitamins.

[0013] In a particular embodiment, the composition comprises one or more of each of seaweeds, enzy mes, and proteins; two or more of microalgae; three or more of each of probiotics and fibers; four or more of each of botanicals, micronutrients, and whole fruit or vegetable powders; and six or more of each of adaptogens. extracts, minerals, and vitamins.

[0014] In a particular embodiment, the composition comprises one or more of each of seaweeds, enzy mes, and proteins; two or more of microalgae; three or more of each of probiotics and fibers; four or more of each of botanicals, micronutrients, and whole fruit or vegetable powders; and seven or more of each of adaptogens, extracts, minerals, and vitamins.

[0015] In a particular embodiment, the composition comprises one or more of each of seaweeds, enzy mes, and proteins; two or more of microalgae; three or more of each of probiotics and fibers; four or more of each of botanicals, micronutrients, and whole fruit or vegetable powders: seven or more of adaptogens; and eight or more of each of extracts, minerals, and vitamins.

[0016] In a particular embodiment, the composition comprises one or more of each of seaweeds, enzymes, and proteins; two or more of microalgae; three or more of each of probiotics and fibers: four or more of each of botanicals, micronutrients, and whole fruit or vegetable powders; seven or more of adaptogens; and nine or more of each of extracts, minerals, and vitamins.

[0017] In a particular embodiment, the composition comprises one or more of each of seaweeds, enzymes, and proteins; two or more of microalgae; three or more of each of probiotics and fibers: four or more of each of botanicals, micronutrients, and whole fruit or vegetable powders; seven or more of adaptogens; and ten or more of each of extracts, minerals, and vitamins.

[0018] In a particular embodiment, the composition comprises one or more of each of seaweeds, enzymes, and proteins; two or more of microalgae; three or more of each of probiotics and fibers; four or more of each of botanicals, micronutrients, and whole fruit or vegetable powders; seven or more of adaptogens; and eleven or more of each of extracts, minerals, and vitamins.

[0019] In a particular embodiment, the composition comprises one or more of each of seaweeds, enzymes, and proteins: two or more of microalgae: three or more of each of probiotics and fibers; four or more of each of botanicals, micronutrients, and whole fruit or vegetable powders; seven or more of adaptogens; and twelve or more of each of extracts, minerals, and vitamins.

[0020] In a particular embodiment, the composition comprises one or more of each of seaweeds, enzymes, and proteins: two or more of microalgae: three or more of each of probiotics and fibers; four or more of each of botanicals, micronutrients, and whole fruit or vegetable powders; seven or more of adaptogens; twelve or more of each of extracts and minerals; and thirteen or more of vitamins.

[0021] In a particular embodiment, the composition comprises one or more of each of seaweeds, enzymes, and proteins: two or more of microalgae: three or more of each of probiotics and fibers; four or more of each of botanicals, micronutrients, and whole fruit or vegetable powders; seven or more of adaptogens; twelve or more of each of extracts and minerals; and fourteen or more of vitamins.

[0022] In a particular aspect of each of the above embodiments, the composition comprises one or more of benfotiamine, Vitamin K2, boron glycinate, molybdenum and four probiotics. In a particular aspect of each of the above embodiments, the composition comprises one or more of benfotiamine, boron glycinate, molybdenum and four probiotics.

[0023] In a particular aspect of each of the above embodiments, the composition comprises one or more of benfotiamine. Vitamin K2, boron glycinate, molybdenum and five probiotics.

[0024] In a particular aspect of each of the above embodiments, the composition comprises one or more of benfotiamine. boron glycinate, molybdenum and five probiotics.

[0025] In a particular aspect of each of the above embodiments, the composition comprises one or more of sophora japonica extract, cocoa extract, and four probiotics.

[0026] In a particular aspect of each of the above embodiments, the composition comprises one or more of sophora japonica extract, cocoa extract, and five probiotics.

[0027] In a particular aspect of each of the above embodiments, the composition comprises one or more of benfotiamine. myo-inositol, sophora japonica extract, cocoa extract, and four probiotics.

[0028] In a particular aspect of each of the above embodiments, the composition comprises one or more of benfotiamine, myo-inositol, sophora japonica extract, cocoa extract, and five probiotics.

[0029] 3. DETAILED DESCRIPTION

[0030] Tire disclosure includes at least the following:

[0031] ( 1 .) A composition comprising: one or more of each of adaptogens, botanicals, seaweeds, enzymes, extracts, fibers, microalgae, micronutrients, minerals, protein, vitamins, and whole fruit or vegetable powders: and three or more of probiotics.

[0032] (2.) A composition comprising: one or more of each of seaweeds, enzymes, and protein; two or more of each of adaptogens, botanicals, extracts, fibers, microalgae, micronutrients, minerals, vitamins, and whole fruit or vegetable powders; and three or more of probiotics.

[0033] (3.) A composition comprising: one or more of each of seaweeds, enzymes, and proteins; two or more of microalgae; and three or more of each of probiotics, adaptogens, botanicals, extracts, fibers, micronutrients, minerals, vitamins, and whole fruit or vegetable powders.

[0034] (4.) A composition comprising: one or more of each of seaweeds, enzymes, and proteins; two or more of microalgae; three or more of each of probiotics and fibers; and four or more of each of adaptogens, botanicals, extracts, micronutrients, minerals, vitamins, and whole fruit or vegetable powders.

[0035] (5.) A composition comprising: one or more of each of seaweeds, enzymes, and protein; two or more of microalgae; three or more of each of probiotics and fibers; four or more of each of botanicals, micronutrients, and whole fruit or vegetable powders; and five or more of each of adaptogens, extracts, minerals, and vitamins.

[0036] (6.) A composition comprising: one or more of each of seaweeds, enzymes, and proteins; two or more of microalgae; three or more of each of probiotics and fibers; four or more of each of botanicals, micronutrients, and whole fruit or vegetable powders; and six or more of each of adaptogens, extracts, minerals, and vitamins.

[0037] (7.) A composition comprising: one or more of each of seaweeds, enzymes, and proteins; two or more of microalgae; three or more of each of probiotics and fibers; four or more of each of botanicals, micronutrients, and whole fruit or vegetable powders; and seven or more of each of adaptogens, extracts, minerals, and vitamins.

[0038] (8.) A composition comprising: one or more of each of seaweeds, enzymes, and proteins; two or more of microalgae; three or more of each of probiotics and fibers; four or more of each of botanicals, micronutrients, and whole fruit or vegetable powders; seven or more of adaptogens; and eight or more of each of extracts, minerals, and vitamins.

[0039] (9.) A composition comprising: one or more of each of seaweeds, enzymes, and proteins; two or more of microalgae; three or more of each of probiotics and fibers; four or more of each of botanicals, micronutrients, and whole fruit or vegetable powders; seven or more of adaptogens; and nine or more of each of extracts, minerals, and vitamins.

[0040] (10.) A composition comprising: one or more of each of seaweeds, enzymes, and proteins; two or more of microalgae; three or more of each of probiotics and fibers; four or more of each of botanicals, micronutrients, and whole fruit or vegetable powders; seven or more of adaptogens; and ten or more of each of extracts, minerals, and vitamins.

[0041] (11.) A composition comprising: one or more of each of seaweeds, enzymes, and proteins; two or more of microalgae; three or more of each of probiotics and fibers; four or more of each of botanicals, micronutrients, and whole fruit or vegetable powders; seven or more of adaptogens; and eleven or more of each of extracts, minerals, and vitamins.

[0042] (12.) A composition comprising: one or more of each of seaweeds, enzymes, and proteins; two or more of microalgae; three or more of each of probiotics and fibers; four or more of each of botanicals, micronutrients, and whole fruit or vegetable powders; seven or more of adaptogens; and twelve or more of each of extracts, minerals, and vitamins.

[0043] (13.) A composition comprising: one or more of each of seaweeds, enzymes, and proteins; two or more of microalgae; three or more of each of probiotics and fibers; four or more of each of botanicals, micronutrients, and whole fruit or vegetable powders; seven or more of adaptogens; twelve or more of each of extracts and minerals; and thirteen or more of vitamins.

[0044] (14.) A composition comprising: one or more of each of seaweeds, enzymes, and proteins; two or more of microalgae; three or more of each of probiotics and fibers; four or more of each of botanicals, micronutrients, and whole fruit or vegetable powders; seven or more of adaptogens; twelve or more of each of extracts and minerals; and fourteen or more of vitamins.

[0045] (15.) The composition of any one of the above (1 .) to (14.), further comprising an excipient.

[0046] (16.) The composition of any one of the above (1.) to (14 ). further comprising a nutraceutically acceptable carrier.

[0047] (17.) The composition of any one of the above ( 1.) to ( 16.), comprising benfotiamine . (18.) The composition of any one of the above (1 .) to (16.), comprising Vitamin K2.

[0048] (19.) The composition of any one of the above (1.) to (16.), comprising boron glycinate.

[0049] (20.) The composition of any one of the above (1 .) to (16 ), comprising molybdenum.

[0050] (21.) The composition of any one of the above (1.) to (16 ), comprising sophorajaponica extract.

[0051] (22.) The composition of any one of the above (1 .) to (16 ), comprising cocoa extract.

[0052] (23.) The composition of any one of the above (1.) to (16 ), comprising myo-inositol.

[0053] (24.) The composition of any one of the above (1.) to (16.), comprising four probiotics.

[0054] (25.) The composition of any one of the above (1.) to (16 ). comprising five probiotics.

[0055] (26.) Tire composition of any one of the above (1.) to (16.), comprising benfotiamine, Vitamin K2, boron glycinate, molybdenum and four probiotics.

[0056] (27.) The composition of any one of the above (1 .) to (16.), comprising benfotiamine. Vitamin K2, boron glycinate, molybdenum and five probiotics.

[0057] (28.) The composition of any one ofthe above (1.) to (16 ). comprising benfotiamine, boron glycinate, molybdenum and four probiotics.

[0058] (29.) Tire composition of any one ofthe above (1.) to (16 ), comprising benfotiamine, boron glycinate, molybdenum and five probiotics.

[0059] (30.) The composition of any one of the above (1 .) to (16.), comprising sophorajaponica extract and four probiotics.

[0060] (31.) The composition of any one of the above (1.) to ( 16.). comprising sophorajaponica extract and five probiotics.

[0061] (32.) The composition of any one of the above (1.) to (16.), comprising cocoa extract and four probiotics.

[0062] (33.) Tire composition of any one ofthe above (1.) to (16.), comprising cocoa extract and five probiotics. (34.) The composition of any one of the above (1.) to (16.), comprising sophorajaponica extract, cocoa extract, and four probiotics.

[0063] (35.) The composition of any one of the above (1.) to (16.), comprising sophorajaponica extract, cocoa extract, and five probiotics.

[0064] (36.) The composition of any one of the above (1 .) to (16.), comprising sophorajaponica extract, cocoa extract, myo-inositol, benfotiamine, and four probiotics.

[0065] (37.) The composition of any one of the above (1.) to (16 ), comprising sophorajaponica extract, cocoa extract, myo-inositol, benfotiamine, and five probiotics.

[0066] (38.) Tire composition of any one of the above (1.) to (37.), wherein the adaptogen is Licorice plant, Reishi Mushroom, Shiitake Mushroom, Ashwagandha, Astragalus, Ginseng, Rhodiola rosea, or combinations thereof.

[0067] (39.) The composition of any one of the above (1.) to (38.), wherein the botanicals are Wheat Grass, Ginger, Slippery Elm, Green tea powder, or combinations thereof.

[0068] (40.) The composition of any one of the above (1 .) to (39.), wherein the seaweed is Fucus vesiculosus.

[0069] (41.) Tire composition of any one of the above (1.) to (40 ), wherein the extracts are Citrus

[0070] Bioflavonoids, Rosehip Fruit extract, Artichoke extract, Sophora japonica extract. Rosemary Leaf extract. Cocoa seed extract, Wolfberry fruit extract, Dandelion extract, Burdock Root extract, Hawthorn berry extract. Bilberry extract, Milk Thistle Seed extract. Grape Seed Extract, Pine bark extract, Black currant extract, Japanese knotweed, or combinations thereof.

[0071] (42.) The composition of any one of the above (1.) to (41.). wherein the fiber is fruit fiber, chicory root, beta glucans, or combinations thereof.

[0072] (43.) Tire composition of any one of the above (1.) to (42 ), wherein the microalgac is Spirulina, Chlorella, or combinations thereof.

[0073] (44.) The composition of any? one of the above (1 .) to (43.), wherein the micronutrient is choline, inositol, alpha lipoic acid, co-enzyme Q10, or combinations thereof. (45.) The composition of any one of the above (1 .) to (44.), wherein the mineral is calcium, potassium, magnesium, zinc, colloidal silica, selenium, manganese, boron, molybdenum, copper, chromium, or combinations thereof.

[0074] (46.) The composition of any one of the above (1.) to (45.). wherein the probiotic is Lacticaseibacillus rhamnosus GG, Lacticaseibacillus casei LC-11, Lactobacillus acidophilus NCFM, Bifidobacterium lactis HN019, Lactiplantibacillus plantarum LP-115, or combinations thereof.

[0075] (47.) The composition of any one of the above (1.) to (46 ). wherein the protein is Pea Protein.

[0076] (48.) Tire composition of any one of the above (1.) to (47.), wherein the vitamin is Vitamin C, Vitamin E, Vitamin K2, Vitamin Bl, Vitamin B6, Vitamin B3, Vitamin B5, Vitamin Bl, Vitamin B2, Vitamin A, Vitamin B9, Vitamin B12, Vitamin B7, or combinations thereof.

[0077] (49.) The composition of any one of the above (1 .) to (48.), wherein the whole fruit or vegetable powder is Papaya, Acerola Cherry. Pineapple, Cocoa Bean, Alfalfa Leaf, Barley leaf, Carrot, Broccoli, Beetroot, or combinations thereof.

[0078] (50.) The composition of any one of the above (1 .) to (49.), further a bulking agent, binding agent, disintegrant, preservative, antioxidant, coloring agent, flavoring agent, sweetening agent, taste masking agent, stabilizer, or any combination thereof.

[0079] (51.) The composition of the above (50.), wherein the composition comprises a flavoring agent.

[0080] (52.) Tire composition of the above (51.), wherein the flavoring agent is eucalyptus, vanilla, citrus oil, lemon oil, orange oil, grape oil, grapefruit oil, citric acid, or a fruit essence.

[0081] (53.) The composition of the above (50.), wherein the composition comprises a sweetening agent.

[0082] (54.) The composition of the above (53.). wherein tire sweetening agent is sucrose, lactose, glucose, fructose, reduced glucose, maltose, xylitol, maltitol. sorbitol, mannitol, lactitol, isomalt, erythritol, polyglycitol, polyglucitol, glycerol, stevia, agave nectar, inverti syrup, maltodextrin, monkfruit, monkfruit extract, allulose, sucralose, aspartame, acesulfame potassium (or Ace-K), advantame, ethyl maltol, neotame, trehalose, raffinose, cellobiose, tagatose, inulin, N-[N-[3-(3-hydroxy-4-methoxyphenyl)propyl]- alpha-aspartyl]-L-phenylalanine 1 -methyl ester, glycyrrhizin, sodium cyclamate, brazzein, miraculin, curculin, pentadin, mabinlin, NHDC, thaumatin. naringin dihydrochalcone, or combinations thereof. (55.) A method for improving gut health, for enhancing energy, for improving focus, for reducing cravings, for improving stress management, for improving health, for promoting healthy aging, for replenishing nutrients, for supporting immune health, for promoting skin health, for promoting hair and nail growth, or for enhancing recovery after physical activity in a subject in need thereof, the method comprising administering an effective amount of a composition of any one of the above (1.) to (54.).

[0083] (56.) A food, food product, food additive, or dietary supplement comprising a composition of any one of the above (1.) to (54.).

[0084] (57.) A kit comprising the composition of any of the above (1.) to (54).

[0085] 3.1 DEFINITIONS

[0086] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as those commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. Tire materials, methods and examples are illustrative only, and are not intended to be limiting. All publications, patents and other documents mentioned herein are incorporated by reference in their entirety.

[0087] Throughout this specification, the word “comprise” or variations such as “comprises” or “comprising” will be understood to imply the inclusion of a stated integer or groups of integers but not the exclusion of any other integer or group of integers. Each instance herein, any of the terms “comprising,” “consisting essentially of.” and “consisting of’ can be replaced with either of the two other terms.

[0088] The term “a” or “an” may mean more than one of an item.

[0089] The terms “and” and “or” may refer to either the conjunctive or disjunctive and mean “and / or”.

[0090] The term “about” means within plus or minus 10% of a stated value. For example, “about 100” would refer to any number between 90 and 110.

[0091] Where a range of values is provided, the range is intended to include each intervening integer value between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the disclosure. For example, if a range of 1 mg to 10 mg is stated, it is understood to expressly include subranges such as from 1 to 3, from 1 to 4, from 1 to 5. from 1 to 6. from 1 to 7, from 1 to 8, from 1 to 9, from 2 to 4, from 2 to 6, from 2 to 8, etc., as well as the individual values within the range, such as 1.1, 2, 2.6, 3, 3.9, 4, 4.2, 5, 5.7, 6, 6.5, 7, 7.4, 8, 8.8, 9, 9.1 and 10.

[0092] The term "‘single dose” refers to a single dosage of a substance given to a subject. A single dose package contains one dosage form, e.g.. one tablet.

[0093] Tire term “unit dose” refers to one single dosage of a substance given to a subject. A unit dose package could contain more than one dosage fonn, e.g., more than one tablet.

[0094] The term “daily dose” refers to the dosage of a substance given to a subject each day.

[0095] The term “nutraceutical” refers to a food, food product, food additive, or dietary supplement that provides health and / or medical benefits, such as preventing, treating and enhancing a condition in a subject, including improving gut health, for enhancing energy, for improving focus, for reducing cravings, for enhancing calm, for improving health, for enhancing recovery after physical activity.

[0096] The term “dietary supplement” is a product intended to supplement a subject's diet and provide additional nutrients that may be lacking or insufficiently provided.

[0097] Tire term “excipient” refers to any substance (a solid, liquid or semi-solid), not itself a therapeutic agent, used as a carrier, diluent, adjuvant, binder, filler, and / or vehicle for delivery of active ingredients to a subject; added to a composition to improve its handling or storage properties; or added to facilitate the formulation of the composition into the desired dosage form for administration. Suitable excipients include fillers, binders, disintegrants, lubricants, glidants, preservatives, flavoring agents, coloring agents, buffering agents, stabilizers, compacting agents, sweeteners, and combinations thereof. Examples of excipients include natural or artificial sweeteners (such as sucrose, lactose, glucose, fructose, reduced glucose, maltose, xylitol, maltitol, sorbitol, mannitol, lactitol, isomalt, erythritol, polyglycitol, polyglucitol, glycerol, stevia, agave nectar, inverti syrup, maltodextrin, monkfruit, monkfruit extract, allulose, sucralose, aspartame, acesulfame potassium (or Ace-K), advantame, ethyl maltol, neotame, trehalose, raffinose, cellobiose, tagatose, inulin, N-[N-[3-(3-hydroxy-4-methoxyphenyl)propyl]-alpha- aspartyl]-L-phenylalanine 1 -methyl ester, glycyrrhizin, sodium cyclamate, brazzein, miraculin, curculin, pentadin, mabinlin, NHDC, thaumatin, and naringin dihydrochalcone); starches (such as tapioca starch, modified tapioca starch, com starch and potato starch); cellulose and its derivatives (such as sodium carboxymethyl cellulose, ethyl cellulose, cellulose acetate, hydroxypropylmethylcellulose, and hydroxypropylcellulose); powdered tragacanth; malt; gelatin; talc; fats or oils (such as lecithin, soy lecithin, sunflower lecithin, egg yok lecithin, canola lecithin, algal oil, peanut oil, cottonseed oil. safflower oil, sesame oil, olive oil, com oil and soybean oil); glycols (such as propylene glycol); polyols (such as glycerin, sorbitol, mannitol and polyethylene glycol); esters, such as ethyl laurate; agar; alginic acid; water; purified water; artificial and natural flavors (such as herbs, spices, fruits, vegetables, aromatic oils (e.g., caraway, clove, lemon, spearmint, rose, and peppermint); ginger; raspberry; maltol; syrups (e.g., citric acid, sarsaparilla, and cherry); glycerin; cocoa; licorice; vanillin; and ethyl vanillin)), and other nontoxic compatible substances employed in oral formulations.

[0098] Tire term “nutraceutically acceptable carrier” refers to any substance (a solid, liquid or semisolid), compatible with tire other ingredients in the nutraceutical composition and used as a carrier, diluent, adjuvant, binder, filler, and / or vehicle for delivery of the nutraceuticals to a subject; added to a nutraceutical composition to improve its handling or storage properties; or added to facilitate the formulation of the nutraceutical composition into the desired dosage form for administration. The nutraceutically acceptable carrier can be wetting agents, bulking agents, thickening agents, granulating agents, coating agents, release-controlling agents, binding agents, buffering agents, suspending agents, lubricating agents, compacting agents, dispersing enhancers, emulsifiers, disintegrants, absorbents, preservatives, antioxidants, surfactants, coloring agents, flavoring agents, sweetening agents, taste masking agents, and stabilizers. Examples of nutraceutically acceptable carriers include natural or artificial sweeteners (such as sucrose, lactose, glucose, fructose, reduced glucose, maltose, xylitol, maltitol, sorbitol, mannitol, lactitol, isomalt, erythritol, polyglycitol, polyglucitol, glycerol, stevia, agave nectar, invert! syrup, maltodextrin, monkfruit, monkfruit extract, allulose, sucralose, aspartame, acesulfame potassium (or Ace-K), advantame, ethyl maltol, neotame, trehalose, raffinose, cellobiose, tagatose, inulin, N-[N-[3-(3-hydroxy-4-methoxyphenyl)propyl]-alpha-aspartyl]-L-phenylalanine 1-methyl ester, glycyrrhizin, sodium cyclamate, brazzein. miraculin, curculin. pentadin. mabinlin. neohesperidin dihydrocbalcone (NHDC), thaumatin, and naringin dihydrochalcone; starches (such as tapioca starch, modified tapioca starch, com starch and potato starch); cellulose and its derivatives (such as sodium carboxymethyl cellulose, ethyl cellulose, cellulose acetate, hydroxypropylmcthylccllulosc, and hydroxypropylcellulose); powdered tragacanth; malt; gelatin; talc; fats or oils (such as lecithin, soy lecithin, sunflower lecithin, egg yok lecithin, canola lecithin, algal oil. peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil, and soybean oil); glycols (such as propylene glycol); polyols (such as glycerin, sorbitol, mannitol, and polyethylene glycol); esters (such as ethyl laurate); agar; alginic acid; water; purified water; artificial and natural flavors (such as herbs, spices, fruits, vegetables, aromatic oils (e.g., caraway, clove, lemon, spearmint, rose, and peppermint)); ginger; raspberry; maltol; syrups (e.g., citric acid, sarsaparilla, and cherry); glycerin; cocoa; licorice; vanillin; and ethyl vanillin)), and other non-toxic compatible substances employed in nutraceutical formulations. The term ‘'amino acid’’ can be essential amino acids, naturally occurring amino acids, or amino acid derivatives and include both the L- and D-configurations. Examples of amino acids include taurine, N-acetylcysteine (NAC), theanine, glycine, phenylalanine, valine, threonine, try ptophan, methionine, leucine, isoleucine, lysine, histidine, cysteine, methionine, carnitine, acetyl carnitine, gamma- aminobutyric acid (GABA), 5 -hydroxytryptophan (5-HTP), glutathione, collagen, and combinations thereof.

[0099] Tire term “effective amount” refers to an amount that is sufficient to achieve the desired result, e.g., improve gut health, enhance energy, improve focus and energy, reduce cravings, for enhance calm, improve health, and / or enhance recovery after physical activity, but is generally insufficient to cause adverse side effects. As is understood in the art, an effective amount can be administered in one or more doses.

[0100] The term “subject” refers to an animal, such as a mammal, including but not limited to, a human. In particular embodiments, the subject is a mammal. In certain embodiments, the subject is a human.

[0101] “Treatment”, “treating” and the like is an approach for obtaining a beneficial or desired result, including clinical results. For purposes of this disclosure, beneficial or desired results include but are not limited to inhibiting and / or suppressing the onset and / or development of a condition or reducing the severity of such condition, such as reducing the number and / or severity of symptoms associated with the condition, increasing the quality of life of those suffering from the condition, decreasing the dose of other medications required to treat the condition, enhancing the effect of another medication a subject is taking for the condition, and / or prolonging survival of subjects having the condition.

[0102] “Prevent”, “preventing” and the like refers to reducing the probability of developing a condition in a subject who does not have but is at risk of developing a condition. A subject “at risk” may or may not have a detectable condition and may or may not have displayed a detectable condition prior to the treatment methods disclosed herein. “At risk” denotes that a subject has one or more so-called risk factors, which are measurable parameters that correlate with development of a condition and are known in the art. A subject having one or more of these risk factors has a higher probability of developing the condition than a subject without such risk factor(s).

[0103] It is to be understood that the various ingredients in the compositions disclosed herein include both conventionally produced and organically produced forms thereof, wherein the term “organically produced” refers to production methods that comply with recognized organic certification standards, such as those set by the USDA National Organic Program or other equivalent regulatory authorities. 3.2 COMPOSITIONS

[0104] The present disclosure provides a composition comprising: one or more of each of adaptogens, botanicals, seaweeds, enzymes, extracts, fibers, microalgae, micronutrients, minerals, protein, vitamins, and whole fruit or vegetable powders: and three or more of probiotics.

[0105] In a first embodiment, the disclosure provides a composition comprising: one or more of each of seaweeds, enzymes, and protein; two or more of each of adaptogens, botanicals, extracts, fibers, microalgae, micronutrients, minerals, vitamins, and whole fruit or vegetable powders: and three or more of probiotics.

[0106] In a second embodiment, the disclosure provides a composition comprising: one or more of each of seaweeds, enzymes, and proteins: two or more of microalgae; and three or more of each of probiotics, adaptogens, botanicals, extracts, fibers, micronutrients, minerals, vitamins, and whole fruit or vegetable powders.

[0107] In a third embodiment, the disclosure provides a composition comprising: one or more of each of seaweeds, enzymes, and proteins; two or more of microalgae; three or more of each of probiotics and fibers: and four or more of each of adaptogens, botanicals, extracts, micronutrients, minerals, vitamins, and whole fruit or vegetable powders.

[0108] In a fourth embodiment, the disclosure provides a composition comprising: one or more of each of seaweeds, enzymes, and protein; two or more of microalgae; three or more of each of probiotics and fibers: four or more of each of botanicals, micronutrients, and whole fruit or vegetable powders: and five or more of each of adaptogens, extracts, minerals, and vitamins.

[0109] In a fifth embodiment, the disclosure provides a composition comprising: one or more of each of seaweeds, enzymes, and proteins; two or more of microalgae; three or more of each of probiotics and fibers; four or more of each of botanicals, micronutrients, and whole fruit or vegetable powders; and six or more of each of adaptogens, extracts, minerals, and vitamins.

[0110] In a sixth embodiment, the disclosure provides a composition comprising: one or more of each of seaweeds, enzymes, and proteins; two or more of microalgae; three or more of each of probiotics and fibers; four or more of each of botanicals, micronutrients, and whole fruit or vegetable powders; and seven or more of each of adaptogens, extracts, minerals, and vitamins. In a seventh embodiment, the disclosure provides a composition comprising: one or more of each of seaweeds, enzymes, and proteins; two or more of microalgae; three or more of each of probiotics and fibers; four or more of each of botanicals, micronutrients, and whole fruit or vegetable powders; seven or more of adaptogens; and eight or more of each of extracts, minerals, and vitamins.

[0111] In an eighth embodiment, the disclosure provides a composition comprising: one or more of each of seaweeds, enzymes, and proteins; two or more of microalgae; three or more of each of probiotics and fibers; four or more of each of botanicals, micronutrients, and whole fruit or vegetable powders; seven or more of adaptogens; and nine or more of each of extracts, minerals, and vitamins.

[0112] In a ninth embodiment, the disclosure provides a composition comprising: one or more of each of seaweeds, enzymes, and proteins; two or more of microalgae; three or more of each of probiotics and fibers; four or more of each of botanicals, micronutrients, and whole fruit or vegetable powders; seven or more of adaptogens; and ten or more of each of extracts, minerals, and vitamins.

[0113] In a tenth embodiment, the disclosure provides a composition comprising: one or more of each of seaweeds, enzymes, and proteins; two or more of microalgae; three or more of each of probiotics and fibers; four or more of each of botanicals, micronutrients, and whole fruit or vegetable powders; seven or more of adaptogens; and eleven or more of each of extracts, minerals, and vitamins.

[0114] In an eleventh embodiment, the disclosure provides a composition comprising: one or more of each of seaweeds, enzymes, and proteins; two or more of microalgae; three or more of each of probiotics and fibers: four or more of each of botanicals, micronutrients, and whole fruit or vegetable powders; seven or more of adaptogens; and twelve or more of each of extracts, minerals, and vitamins.

[0115] In a twelfth embodiment, the disclosure provides a composition comprising: one or more of each of seaweeds, enzymes, and proteins; two or more of microalgae; three or more of each of probiotics and fibers; four or more of each of botanicals, micronutrients, and whole fruit or vegetable powders: seven or more of adaptogens: twelve or more of each of extracts and minerals; and thirteen or more of vitamins.

[0116] In a thirteenth embodiment, the disclosure provides a composition comprising: one or more of each of seaweeds, enzymes, and proteins; two or more of microalgae; three or more of each of probiotics and fibers: four or more of each of botanicals, micronutrients, and whole fruit or vegetable powders; seven or more of adaptogens; twelve or more of each of extracts and minerals; and fourteen or more of vitamins. In one aspect of each of the embodiments described above, the composition comprises benfotiamine.

[0117] In a second aspect of each of the embodiments described above, the composition comprises Vitamin K2.

[0118] In a third aspect of each of the embodiments described above, the composition comprises boron glycinate.

[0119] In a fourth aspect of each of the embodiments described above, the composition comprises molybdenum.

[0120] In a fifth aspect of each of the embodiments described above, the composition comprises four probiotics.

[0121] In a sixth aspect of each of the embodiments described above, the composition comprises five probiotics.

[0122] In a seventh aspect of each of the embodiments described above, the composition comprises benfotiamine, Vitamin K2, boron glycinate, molybdenum and four probiotics.

[0123] In an eighth aspect of each of the embodiments described above, the composition comprises benfotiamine, Vitamin K2, boron glycinate, molybdenum and five probiotics.

[0124] In a ninth aspect of each of the embodiments described above, the composition comprises benfotiamine, boron glycinate, molybdenum and four probiotics.

[0125] In a tenth aspect of each of the embodiments described above, the composition comprises benfotiamine, boron glycinate, molybdenum and five probiotics.

[0126] In an eleventh aspect of each of the embodiments described above, the composition comprises Sophorajaponica extract.

[0127] In a twelfth aspect of each of the embodiments described above, tire composition comprises cocoa extract.

[0128] In a thirteen aspect of each of the embodiments described above, the composition comprises myoinositol. In a fourteenth aspect of each of the embodiments described above, the composition comprises Sophorajaponica extract and cocoa extract.

[0129] In a fourteenth aspect of each of the embodiments described above, the composition comprises Sophora japonica extract, cocoa extract, benfotiamine, and myo-inositol.

[0130] Tire present disclosure also provides a composition comprising: one or more of each of adaptogens, botanicals, enzymes, extracts, fibers, microalgae, micronutrients, minerals, protein, vitamins, and whole fruit or vegetable powders; and two or more of probiotics.

[0131] In a first embodiment, the disclosure provides a composition comprising: one or more of each of enzymes, fiber and protein; two or more of each of adaptogens, botanicals, extracts, microalgac, micronutrients, minerals, vitamins, whole fruit or vegetable powders and probiotics.

[0132] In a second embodiment, the disclosure provides a composition comprising: one or more of each of enzymes, fiber and protein; two or more of probiotics; and three or more of each of adaptogens, botanicals, extracts, microalgae, micronutrients, minerals, vitamins, and whole fruit or vegetable powders.

[0133] In a third embodiment, the disclosure provides a composition comprising: one or more of each of enzymes, fiber, and protein; two or more of probiotics; three or more of each of botanicals, microalgae, vitamins, and whole fruit or vegetable powders; and four or more of each of adaptogens, extracts, micronutrients, and minerals.

[0134] In a fourth embodiment, the disclosure provides a composition comprising: one or more of each of enzymes, fiber and protein; two or more of probiotics; three or more of each of botanicals, microalgae, vitamins, and whole fruit or vegetable powders; four or more of micronutrients; and five or more of each of adaptogens. extracts, minerals, vitamins, and whole fruit or vegetable powders.

[0135] In a fifth embodiment, the disclosure provides a composition comprising: one or more of each of enzymes, fiber and protein; two or more of probiotics; three or more of each of botanicals, microalgae, vitamins, and whole fruit or vegetable powders; four or more of micronutrients; five or more of adaptogens; and six or more of each of extracts, minerals, vitamins and whole fruit or vegetable powders.

[0136] In a sixth embodiment, the disclosure provides a composition comprising: one or more of each of enzymes, fiber and protein; two or more of probiotics; three or more of each of botanicals, microalgae, vitamins, and whole fruit or vegetable powders; four or more of micronutrients; and five or more of adaptogens; ten or more of each of extracts, minerals, vitamins and whole fruit or vegetable powders. In a seventh embodiment, the disclosure provides a composition comprising: one or more of each of enzymes, fiber and protein; two or more of probiotics; three or more of each of botanicals, microalgae, vitamins, and whole fruit or vegetable powders; four or more of micronutrients; five or more of adaptogens; ten or more of whole fruit or vegetable powders; and eleven or more of each of extracts, minerals, and vitamins.

[0137] In an eighth embodiment, the disclosure provides a composition comprising: one or more of each of enzymes, fiber and protein; two or more of probiotics; three or more of each of botanicals, microalgae, vitamins, and whole fruit or vegetable powders; four or more of micronutrients; five or more of adaptogens; ten or more of whole fruit or vegetable powders; eleven or more of minerals; and thirteen or more of each of extracts and vitamins.

[0138] In a ninth embodiment, the disclosure provides a composition comprising: one or more of each of enzymes, fiber and protein; two or more of probiotics; three or more of each of botanicals, microalgae, vitamins, and whole fruit or vegetable powders; four or more of micronutrients; five or more of adaptogens; ten or more of whole fruit or vegetable powders; eleven or more of minerals; thirteen or more of extracts; and fourteen or more of vitamins.

[0139] The adaptogens that may be used in the compositions disclosed herein include Licorice plant, Licorice root, Licorice Root Powder, Glycyrrhiza glabra root and rhizome powder (Licorice root), Anise, Fennel seed, Marshmallow Root, Deglycyrrhizinated Licorice, Chamomile, Reishi Mushroom, Reishi Mushroom Powder, Ganoderma lucidum Powder, Shiitake Mushroom, Shiitake Mushroom Powder, Lentinula edodes powder (Shiitake mushroom), Cordyceps, Cordyceps Mushroom, Turkey Tail Mushroom, Lion’s Mane Mushroom, Chaga Mushroom, Maitake Mushroom, Astragalus, Astragalus Root, Astragalus Root Extract 4: 1, Ashwagandha, Ashwagandha root. Ashwagandha Root Extract 5: 1, Withania somnifera root extract 5 : 1 (Ashwagandha), withania somnifera root dry. Panax Ginseng, Panax quinquefolius, Holy Basil, Schisandra Berry. Echinacea, Maca, Ginseng, Ginseng Siberian extract 10: 1 (NLT 0.8% eleutherosides), Siberian ginseng, Siberian Ginseng Extract 0.8%, Rhodiola rosea, Rhodiola Rosea root, Rhodiola Rosea Root Extract, Rhodiola Rosea Root Extract (15: 1), and combinations thereof. In various embodiments, the adaptogens may be Licorice plant, Reishi Mushroom, Shiitake Mushroom, Ashwagandha, Astragalus, Ginseng. Rhodiola rosea, and combinations thereof. In various embodiments, the adaptogens may be licorice root power, Reishi Mushroom Powder, shiitake mushroom powder, ashwagandha root extract 5: 1, astragalus root extract 4: 1, Siberian ginseng extract 0.8%, Rhodiola Rosea Root extract (15: 1), and combinations thereof. In various embodiments, the adaptogens may be Reishi Mushroom, Ginseng, Licorice plant, Shiitake Mushroom, Ashwagandha, and combinations thereof. In various embodiments, the adaptogens may be Reishi Mushroom, Ginseng Siberian extract, Licorice plant, shiitake mushroom, ashwagandha, and combinations thereof.

[0140] The botanicals that may be used in the compositions disclosed herein include Wheat Grass, Wheat Grass Leaf Powder, Triticum vulgare leaf powder (Wheatgrass), Wheatgrass juice. Barley grass. Alfalfa grass, Moringa leaf, Spinach, Kale, Dandelion greens, Ginger, Zingiber officinale rhizome powder (Ginger), Ginger Root powder, Turmeric, Galangal, Cardamom, Cloves, Cinnamon, Black Pepper, Fennel Seeds, Chamomile, Coriander, Peppermint, Slippery Elm, Ulmus rubra inner bark powder (Slippery elm), Slippery Elm Inner Bark Powder, Marshmallow root, Plantain leaf, Aloe vera. Okra, Fenugreek seed, Chickweed, Irish moss, Flaxseed, Psyllium husk, Mullein leaf, chia seed, Green tea powder, matcha green tea, Green tea. White tea, Oolong tea, Rooibos tea, Hibiscus tea, Chamomile tea, triphala. Emblica officinalis, Terminalia bellerica, Terminalia chebula, and combinations thereof. In various embodiments, the botanicals may be Wheat Grass, Ginger, Slippery Elm, Green tea powder, and combinations thereof. In various embodiments, the botanicals may be Wheat Grass Leaf Powder, Ginger Root Powder, Slippery Elm Inner Bark Powder, Matcha green tea, and combinations thereof. In various embodiments, the botanicals may be Wheat Grass. Slippery Elm, Ginger, and combinations thereof. In various embodiments, the botanicals may be Triticum vulgare leaf powder (Wheatgrass), Zingiber officinale rhizome powder (Ginger), Ulmus rubra inner bark powder (Slippery7elm), and combinations thereof.

[0141] The seaweed that may be used in the compositions disclosed herein include Fucus vesiculosus, Fucus vesiculosus Whole Plant Powder (Bladderwrack). Kelp, Wakame, Irish Moss, Dulse, Spirulina. Chlorella, Nori, Sea lettuce, and combinations thereof. In various embodiments, the seaweed may be Fucus vesiculosus. In various embodiments, the seaweed may be Fucus vesiculosus Whole Plant Powder (Bladdcrwrack).

[0142] The enzymes that that may be used in the compositions disclosed herein include Digestive enzyme, Proteolytic enzymes, Bromelain, Bromelain 2000, Papain, Pancreatin, Trypsin, Serrapeptase, Protease, Alpha-Galactosidase, Lipase, Amylase, Digestive Bitters, lactase, and combinations thereof. In various embodiments, the enzyme may be Proteolytic enzymes. In various embodiments, the enzyme may be Digestive enzymes. In various embodiments, the enzyme may be Bromelain. In various embodiments, the enzyme may be Bromelain 2000 GDU.

[0143] The extracts that may be used in the compositions disclosed herein include Citrus Bioflavonoids, Citrus Bioflavonoids Extract, Citrus Bioflavonoids 35%, Quercetin, Rutin, Hesperidin, Diosmin, Resveratrol, Kaempferol, Ginkgo Biloba, Ginkgo biloba extract, Pycnogenol, limonene. Rosehip fruit, Rosa canina extract 4: 1 (Rosehip), Rosehip fruit extract. Rosehip Fruit Extract 4: 1, Camu camu extract, Amla extract, Sea Buckthorn extract, Elderberry extract, Cranberry extract, Goji berry extract, Artichoke, Artichoke extract, Artichoke Extract 15: 1, Cynara scolymus Leaf Ext Dry Cone (15: 1) (Globe Artichoke), Boldo leaf extract, Holy Basil. Schisandra berry extract, inulin, Jerusalem artichoke, Japanese pagoda tree, Sophora japonica extract. Sophora japonica extract (NLT 95% rutin), Aesculus hippocastanum, Ruscus aculeatus, Hamamelis virginiana, Pinus pinaster, Centella asiatica. Trifolium pratense, Salix alba, Filipendula ulmaria, Quercetin, Rosemary, Rosmarinus officinalis ext. 4: 1 (Rosemary), Roseman' Leaf extract, Rosemary Leaf Extract 4: 1, Thyme extract, Sage extract, Oregano extract, Basil extract, Lemon balm extract, Origanum majorana, Lavender extract, Cinnamon extract, cocoa extract, Coco seed extract, Cacao nibs, Cocoa powder, Epicatechin, flavonols, Wolfberry, Wolfberry Fruit Extract, Wolfberry Fruit Extract 4: 1 (Goji). Lycium barbarum fruit extract 4: 1 (Wolfberry), Lycium barbarum fruit dry, Acai berry extract, Blackberry extract, Blueberry extract. Raspberry extract, Pomegranate extract, mango, kiwi, guava, black cherry, tart cherry, Dandelion, Dandelion extract. Dandelion Extract 4: 1, Taraxacum officinale extract (4: 1) (Dandelion), taraxacum officinale whole plant, Schisandra extract, Schisandra Berry, Yellow dock root, Yellow dock root extract, Echinacea, Maca, Cordyceps, Burdock Root, Burdock Root extract, Burdock Root Extract 4: 1, Arctium Lappa L. root Ext (4: 1) (Burdock), Arctium lappa root (Burdock), Gentian root, Oregon grape root. Hawthorn berry, Hawthorn berry extract. Hawthorn Berry Extract 10: 1, Crataegus monogyna fruit extract 10: 1 (Hawthorn), Bilberry, Bilberry extract. Bilberry Extract 100: 1, Vaccinium myrtillus fruit extract 100: 1 (Bilberry), Milk Thistle, Milk Thistle Seed Extract, Milk Thistle Seed Extract 80%, Silybum marianum seed extract, dry cone 70: 1 (Milk thistle), silybum marianum seed dry, Schisandra Berry, Globe Artichoke, Chanca Piedra, Greater Celandine, Blessed thistle, Barberry root bark, Grape seed, Grape Seed extract, Grape Seed Extract 120: 1, Vitis vinifera seed extract 120: 1 (Grape Seed), vitis vinifera seed dry, Pine bark extract, Black currant extract, Japanese knotweed. Astragalus root, Astragalus membranaceus Root Ext Dry Cone (4: 1). Astragalus membranaceus Root Dry, Acerola, Malpighia punicifolia fruit extract. 4: 1 (Acerola), and combinations thereof. In various embodiments, the extracts may be Citrus Bioflavonoids, Rosehip Fruit extract, Artichoke extract, Sophora japonica extract, Roseman' Leaf extract, Cocoa seed extract, Wolfberry fruit extract, Dandelion extract. Burdock Root extract, Hawthorn berry extract, Bilberry extract, Milk Thistle Seed extract, Grape Seed Extract, Pine bark extract, Black currant extract. Japanese knotweed, and combinations thereof. In various embodiments, the extracts may be Citrus Bioflavonoids. Rosehip Fruit, Artichoke, Japanese pagoda tree, Rosemary, cocoa extract. Wolfberry, Dandelion, Burdock Root, Haw thorn berry, Bilberry, Milk Thistle, Grape Seed, and combinations thereof. In various embodiments, the extracts may be Citrus Bioflavonoids 35%, Rosehip Fruit Extract 4: 1, Artichoke Extract 15: 1, Sophora japonica extract, Rosemary Leaf Extract 4: 1, Cocoa seed extract, Wolfberry Fruit Extract 4: 1 (Goji), Dandelion Extract 4: 1, Burdock Root Extract 4: 1, Hawthorn Berry Extract 10: 1, Bilberry Extract 100: 1, Milk Thistle Seed Extract 80%, Grape Seed Extract 120: 1, and combinations thereof. In various embodiments, the extracts may be Burdock root, Astragalus Root, Citrus Bioflavonoids Extract, Hawthorn berry, Artichoke, Wolfberry. Acerola, rosehip fruit, Rosemary. Milk thistle, Japanese pagoda tree, Dandelion, Bilberry, Grape Seed, and combinations thereof. In various embodiments, the extracts may be Arctium Lappa L. root Ext (4: 1) (Burdock), Astragalus membranaceus Root Ext Dry Cone (4: 1), Citrus Bioflavonoids Extract, Crataegus monogyna fruit extract 10: 1 (Hawthorn), Cynara scolymus Leaf Ext Dry Cone (15: 1) (Globe Artichoke), Lycium barbarum fruit extract 4: 1 (Wolfberry), Malpighia punicifolia fruit extract. 4: 1 (Acerola), Rosa canina extract 4: 1 (Rosehip), Rosmarinus officinalis ext. 4: 1 (Rosemary), Silybum marianum seed extract, dry cone 70: 1 (Milk thistle). Sophora japonica extract, Taraxacum officinale extract (4: 1) (Dandelion), Vaccinium myrtillus fruit extract 100: 1 (Bilberry), Vitis vinifera seed extract 120: 1 (Grape Seed), and combinations thereof.

[0144] Tire fiber that may be used in the compositions disclosed herein include Fruit fiber, Apple Fiber, Pear fiber, Kiwi fiber, Guava fiber, Psyllium husk, Flaxseed meal. Acacia fiber, Konjac root fiber, pectin, Chicory root, Inulin. Inulin (from chicory root), beta glucans, Beta Glucans 70%, oat extract, mushroom extract, Oligofructose / Fructooligosaccharides / Galactooligosaccharides. Jerusalem artichoke, Konjac root fiber. Resistant starch, Larch arabinogalactan, Human milk oligosaccharides (HMOs), and combinations thereof. In various embodiments, the fiber may be Fruit fiber, Chicory root, beta glucans, and combinations thereof. In various embodiments, the fiber may be Apple Fiber, Inulin, beta glucans, and combinations thereof. In various embodiments, the fiber may be chicory root. In various embodiments, the fiber may be apple fiber. In various embodiments, the fiber may be Inulin.

[0145] Tire microalgae that may be used in the compositions disclosed herein include Spirulina, Spirulina Powder, Spirulina platensis powder, Blue-green algae, kelp, Fucus vesiculosus whole plant powder dry cone (5: 1) (kelp), nori, dulse, Chlorella, Chlorella Powder, Chlorella vulgaris Pow der, and combinations thereof. In various embodiments, the microalgae may be Spirulina, Chlorella, and combinations thereof. In various embodiments, the microalgae may be Spirulina Powder, Chlorella Pow der, and combinations thereof. In various embodiments, the microalgae may be Chlorella, kelp, Spirulina and combinations thereof. In various embodiments, the microalgae may be Chlorella, vulgaris Powder, Fucus vesiculosus whole plant powder dry cone (5: 1) (kelp), Spirulina platensis powder, and combinations thereof.

[0146] The micronutrients that may be used in the compositions disclosed herein include Choline,

[0147] Choline L-Bitartrate, Alpha-Glycerophosphocholine, CDP-Choline, Phosphatidylcholine, Choline Citrate, Inositol, Myo-inositoL D-chiro-inositoL Inositol hexaphosphate, D-chiro-inositoL Inositol hexaphosphate. Alpha Lipoic Acid, Alpha Lipoic Acid (NLT 99%), R-lipoic acid, Co-enzyme Q10, Ubidecarenone (Coenzyme Q10), Ubiquinol, Pyrroloquinoline quinone, ubiquinone, TMG (trimethylglycine) and combinations thereof, hi various embodiments, the micronutrients may be Choline, Inositol, Alpha Lipoic Acid, Co-enzyme Q10, and combinations thereof. In various embodiments, the micronutrients may be Choline L-Bitartrate, Myo-inositol, Alpha Lipoic Acid, Ubidecarenone (CO-enzyme Q10), and combinations thereof. In various embodiments, the micronutrients may be Alpha Lipoic Acid, Choline, Inositol, Co-enzyme Q 10, and combinations thereof. In various embodiments, the micronutrients may be Alpha Lipoic Acid, Choline L-Bitartrate, Inositol (myo-inositol), Ubidecarenone (Co-enzyme Q10), and combinations thereof.

[0148] The minerals that may be used in the compositions disclosed herein include Calcium, Calcium Citrate, Calcium Citrate Powder, Calcium carbonate, Calcium Phosphate, Tricalcium phosphate. Calcium lactate, Calcium citrate malate, calcium hydroxyapaetite, Potassium, Dipotassium Phosphate, Potassium phosphate, Potassium Phosphate Dibasic, Potassium citrate, Potassium bicarbonate, Magnesium, Magnesium Bisglycinate, Magnesium citrate, Magnesium oxide, Magnesium chloride, Magnesium malate, Magnesium glycinate. Magnesium gluconate. Magnesium taurate. magnesium L-threonate, Dimagnesium Malate, Zinc, Zinc Citrate, Zinc Carnosine, Zinc gluconate, Zinc picolinate. Zinc sulfate, Zinc citrate, Zinc citrate dihydrate, Zinc bisglycinate, Zinc orotate, silica, Colloidal silica, Silica Colloidal Hydrated, silica colloidal hydrated, silicon dioxide, selenium, selenium yeast, Selenium yeast (2000ppm), Selenomethionine, Sodium selenite, Manganese, Manganese Amino Acid Chelate, Manganese gluconate, Manganese bisglycinates, Manganese sulfate, Manganese citrate, Manganese picolinate, Boron. Boron glycinate, Bioorganic Boron glycinate 10%. Boron citrate. Boron sulfate, Boron amino acid complexes (e.g., arginine, asparatate, lysine, and the like). Molybdenum, Molybdenum glycinate, Molybdenum citrate, Molybdenum picolinate, Molybdenum sulfate, Molybdenum trit, Copper, Copper Gluconate, Copper Gluconate 13%, Copper citrate, Copper sulfate, Copper oxide, Copper amino acid complexes (e.g., glycine, lysine, and the like), Chromium, Chromium Picolinate, Chromium polynicotinate, Chromium chloride. Chromium citrate, Chromium yeast, and combinations thereof. In various embodiments, the minerals may be Calcium, Potassium, Magnesium, Zinc, Colloidal silica. Selenium, Manganese, Boron, Molybdenum, Copper, Chromium, and combinations thereof. In various embodiments, the minerals may be Calcium citrate powder, Dipotassium Phosphate, Magnesium Bisglycinatc, Zinc Citrate, Dimagncsium Malate, Colloidal silica hydrated - Sipcmat 22S, Selenium yeast (2000ppm), Manganese Amino Acid Chelate, Boron glycinate, Molybednum glycinate, Copper Gluconate, Chromium Picolinate, and combinations thereof. In various embodiments, the minerals may be Calcium citrate powder, Dipotassium Phosphate, Magnesium gluconate. Zinc gluconate. Dimagnesium Malate, Colloidal silica hydrated - Sipemat 22S, Manganese Amino Acid Chelate, Boron glycinate, Molybednum glycinate, Copper Gluconate, Chromium Picolinate, and combinations thereof. In various embodiments, the minerals may be Calcium phosphate, Calcium, Chromium, Copper, Magnesium, Manganese, Potassium Phosphate. Selenium, Silica, Zinc, Molybdenum, and combinations thereof. In various embodiments, the minerals may be Tri calcium phosphate, Calcium Citrate. Chromium Picolinate, Copper Gluconate, Magnesium bisglycinate, Manganese bisglycinates. Potassium Phosphate Dibasic, Selenium enriched yeast, Silicon dioxide, Zinc citrate, Molybdenum trit, and combinations thereof.

[0149] The probiotics that may be used in the compositions disclosed herein include Lacticaseibacillus rhamnosus, Lacticaseibacillus rhamnosus GG, Lacticaseibacillus casei, Lacticaseibacillus casei LC-11 , Lactobacillus acidophilus. Lactobacillus acidophilus NCFM, Bifidobacterium lactis, Bifidobacterium lactis HN019, Bifidobacterium lactis Bbl2' . Bifidobacterium bifidum, Lactiplantibacillus plantarum, Lactiplantibacillus plantarum LP-115, Saccharomyces boulardii, Lactobacillus plantarum, Lactobacillus plantarum DR7, and combinations thereof. In various embodiments, the probiotics may be Lacticaseibacillus rhamnosus GG, Lacticaseibacillus casei LC-11, Lactobacillus acidophilus NCFM. Bifidobacterium lactis FINO 19, 1 lactiplantibacillus plantarum LP-1 15, and combinations thereof. In various embodiments, the probiotics may be Bifidobacterium bifidum, Lactobacillus acidophilus, and combinations thereof.

[0150] The proteins that may be used in the compositions disclosed herein include Pea Protein, Pea Protein Isolate, Pea Protein 80%, Rice protein. Hemp protein, Soy protein, sunflower seed protein, pumpkin seed protein, fava bean protein, lentil protein, flaxseed protein, Algae protein, watermelon seed protein, collagen, colostrum, whey protein concentrate, whey protein isolate, and combinations thereof. In various embodiments, the protein may be Pea Protein. In various embodiments, the protein may be Pea Protein 80%. In various embodiments, the protein may be Pea Protein Isolate.

[0151] Tire vitamins that may be used in the compositions disclosed herein include 5- methyltetrahydrofolate (5-MTHF) (Folate), Folic acid, Folinic Acid, Vitamin A, Beta carotene, Beta carotene (NLF 10%), Vitamin A Palmitate, Retinyl Acetate. Retinoic Acid Derivatives, Vitamin B Complex, Vitamin Bl, Benfotiamine, Thiamine, Thiamine mononitrate. Thiamine hydrochloride, Sulbutiamine, Thiamine Cocarboxylase, Vitamin B2, Riboflavin, Riboflavin-5’ -Phosphate, Vitamin B3, Niacinamide, Niacin (Nicotinic Acid), Nicotinamide riboside, Nicotinamide mononucleotide, Inositol hexanicotinate, Nicotinoyl-GABA, Nicotinamide Mononucleotide (NMN), Vitamin B5, Calcium Pantothenate, D-Pantothenic Acid, Pantethine, Vitamin B6, Pyridoxal-5-phosphate monohydrate. Pyridoxine Hydrochloride, Pyridoxamine, Vitamin B7, D-Biotin, Biotinamide, Biotin-Dextrin Complex, Biotinylated Proteins, Vitamin B9, L-5 -Methylfolate Calcium, Calcium pantothenate, Vitamin B12, Mecobalamin (Methylcobalamin), Cyanocobalamin, Hydroxocobalamin, Hydroxocobalamin acetate, Vitamin C, Ascorbic Acid, Sodium ascorbate, Calcium ascorbate, Magnesium ascorbate, Vitamin E, Mixed-tocopherol Vitamin E, Alpha-tocopherol, Gamma-tocopherol, D-alpha tocopheryl acid succinate, Tocotrienols, Vitamin K2, Vitamin K2 (menaquinone-7), Menaquinone-4, Menaquinone-9, vitamin KI, and combinations thereof. In various embodiments, the vitamins may be Vitamin C, Vitamin E, Vitamin K2, Vitamin Bl, Vitamin B6, Vitamin B3, Vitamin B5, Vitamin B2, Vitamin A, Vitamin B9, Vitamin B12, Vitamin B7, and combinations thereof. In various embodiments, the vitamins may be Ascorbic Acid, Mixed-tocopherol Vitamin E, Vitamin K2 (menaquinone-7), Benfotiamine, Pyridoxal-5-phosphate monohydrate, Niacinamide, Niacin (nicotinic acid), Calcium Pantothenate, Thiamine Hydrochloride, Riboflavin (Vitamin B2), Beta carotene, L-5 -Methylfolate Calcium, Mecobalamin (Methylcobalamin), D- Biotin, and combinations thereof. In various embodiments, the vitamins may be Ascorbic Acid, Mixed- tocopherol Vitamin E, Vitamin K2 (menaquinone-7), Pyridoxine hydrochloride, Niacinamide, Niacin (nicotinic acid), Calcium Pantothenate, Riboflavin (Vitamin B2), Beta carotene, L-5 -Methylfolate Calcium, hydroxocobalamin acetate, D-Biotin, and combinations thereof. In various embodiments, the vitamins may be Vitamin B9, Vitamin C, Vitamin A, Vitamin B7. Vitamin B5, Vitamin E, Vitamin B12, Vitamin B3, Vitamin B3, Vitamin B6, Vitamin B2, Vitamin Bl, Vitamin K2, and combinations thereof. In various embodiments, the vitamins may be 5-MTHF (Folate), Ascorbic Acid, Beta carotene (Vitamin A), Biotin (Vitamin B7), Calcium pantothenate (Vitamin B5), D-alpha tocopheryl acid succinate (Vitamin E), Methylcobalamin (Vitamin B12), Niacin (Vitamin B3), Niacinamide (Vitamin B3), Pyridoxal-5- phosphate monohydrate (Vitamin B6), Riboflavin (Vitamin B2), Thiamine hydrochloride (Vitamin Bl). Vitamin K2 (as menaquinone-7), and combinations thereof.

[0152] Hie whole fruit or vegetable powders that may be used in the compositions disclosed herein include Papaya, Carica papaya Powder (Papaya), Papaya Fruit powder, Mango powder, Kiwi powder. Guava powder, Cranberry powder, Acerola Cherry powder, Acerola Cherry extract, Acerola Cherry Extract 4: 1, Black cherry powder, Tart cherry powder. Ananas sativus fruit powder (Pineapple), pineapple, pineapple powder, pineapple fruit powder, Malus sp. fruit powder (Apple), Apple, pear, Cocoa powder, Cocoa Bean, Cocoa Bean powder, Cacao nibs, Carob powder, Alfalfa, Alfalfa leaf, Alfalfa Leaf powder, Mcdicago sativa leaf powder (Alfalfa), Moringa powder, kale powder, spinach powder, Spinacia oleracea leaf powder (Spinach), Swiss Chard powder, Collard Green powder, Dandelion leaf powder, Hordeum vulgare leaf powder (Barley), Barley, Barley leaf. Barley Leaf Powder, Carrot, carrot powder. Carrot Root Powder, Dacus carota Root Powder (Carrot), Sweet Potato powder. Pumpkin powder, Butternut squash powder, parsnip powder, Broccoli, Broccoli powder, Broccoli Sprout Powder, Broccoli Leaf, Brassica oleracea Powder (Broccoli), Brussels Sprout Powder, Cabbage Powder, Arugula Powder, Arugula leaf powder, Beetroot, Beetroot Powder, Beet Greens powder, Beta vulgaris Root Powder (Beet root), Wheatgrass Powder, Watercrest powder, and combinations thereof. In various embodiments, the whole fruit or vegetable powders may be Papaya, Acerola Cherry. Pineapple, Cocoa Bean, Alfalfa Leaf, Barley leaf, Carrot, Broccoli, Beetroot, and combinations thereof. In various embodiments, the whole fruit or vegetable powders may be Papaya Fruit powder, Acerola Cherry extract, pineapple fruit powder. Cocoa Bean powder, Alfalfa Leaf powder, Barley Leaf Powder, Carrot Root Powder, Broccoli powder, Beetroot Powder, and combinations thereof. In various embodiments, the whole fruit or vegetable powders may be Pineapple, Apple, Cocoa Bean. Beetroot. Broccoli, Papaya, Carrot. Barley. Alfalfa, Spinach, and combinations thereof. In various embodiments, the whole fruit or vegetable powders may be Ananas sativus fruit powder (Pineapple), Malus sp. fruit powder (Apple), Cocoa Powder, Beta vulgaris Root Powder (Beet root), Brassica oleracea Powder (Broccoli), Carica papaya Powder (Papaya), Dacus carota Root Powder (Carrot), Hordeum vulgare leaf pow der (Barley), Medicago sativa leaf powder (Alfalfa), Spinacia oleracea leaf pow der (Spinach), and combinations thereof.

[0153] In some embodiments, per daily dosage, the composition comprises an adaptogen, as disclosed herein, in an amount of about 1 mg to about 500 mg, about 5 mg to about 500 mg, about 10 mg to about 500 mg, about 15 mg to about 500 mg, about 25 mg to about 500 mg, about 50 mg to about 500 mg, about 100 mg to about 500 mg, about 200 mg to about 500 mg, about 300 mg to about 500 mg, about 400 mg to about 500 mg, about 1 mg to about 450 mg. about 1 mg to about 400 mg, about 2 mg to about 400 mg, about 3 mg to about 400 mg, about 4 mg to about 400 mg, about 5 mg to about 400 mg. about 10 mg to about 400 mg, about 15 mg to about 400 mg, about 20 mg to about 400 mg, about 1 mg to about 350 mg, about 1 mg to about 300 mg, about 1 mg to about 250 mg, about 1 mg to about 200 mg, about 1 mg to about 150 mg, about 2 mg to about 150 mg, about 3 mg to about 150 mg, about 4 mg to about 150 mg, about 5 mg to about 150 mg, about 1 mg to about 100 mg. about 2 mg to about 100 mg, about 3 mg to about 100 mg. about 4 mg to about 100 mg, about 5 mg to about 100 mg, about 10 mg to about 100 mg. about 15 mg to about 100 mg, about 1 mg to about 50 mg, about 1 mg to about 25 mg, or about 1 mg to about 10 mg. In one embodiment, the amount of adaptogen in the composition is about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg, about 21 mg, about 22 mg, about 23 mg, about 24 mg, about 25 mg. about 30 mg, about 35 mg, about 40 mg. about 50 mg. about 60 mg. about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, or about 500 mg.

[0154] In some embodiments, per daily dosage, the composition comprises a botanical, as disclosed herein, in an amount of about 1 mg to about 500 mg, about 5 mg to about 500 mg, about 10 mg to about 500 mg, about 15 mg to about 500 mg, about 25 mg to about 500 mg, about 50 mg to about 500 mg, about 100 mg to about 500 mg, about 200 mg to about 500 mg, about 300 mg to about 500 mg, about 400 mg to about 500 mg, about 1 mg to about 450 mg, about 1 mg to about 400 mg, about 2 mg to about 400 mg, about 3 mg to about 400 mg, about 4 mg to about 400 mg, about 5 mg to about 400 mg. about 10 mg to about 400 mg, about 15 mg to about 400 mg, about 20 mg to about 400 mg, about 40 mg to about 400 mg, about 60 mg to about 400 mg, about 80 mg to about 400 mg, about 100 mg to about 400 mg, about 1 mg to about 350 mg, about 1 mg to about 300 mg, about 1 mg to about 250 mg, about 1 mg to about 200 mg, about 1 mg to about 150 mg, about 2 mg to about 150 mg, about 3 mg to about 150 mg, about 4 mg to about 150 mg, about 5 mg to about 150 mg. about 1 mg to about 100 mg, about 2 mg to about 100 mg, about 3 mg to about 100 mg, about 4 mg to about 100 mg. about 5 mg to about 100 mg, about 10 mg to about 100 mg. about 15 mg to about 100 mg, about 20 mg to about 100 mg. about 25 mg to about 100 mg, about 1 mg to about 50 mg, about 1 mg to about 25 mg, or about 1 mg to about 10 mg. In one embodiment, the amount of botanical in the composition is about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg. about 20 mg, about 21 mg, about 22 mg. about 23 mg. about 24 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg. about 80 mg. about 90 mg. about 100 mg, about

[0155] 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about

[0156] 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about

[0157] 475 mg, about 500 mg, about 525 mg, about 550 mg, about 575 mg, or about 600 mg.

[0158] In some embodiments, per daily dosage, the composition comprises seaweed, as disclosed herein, in an amount of about 1 mg to about 50 mg, about 5 mg to about 50 mg, about 10 mg to about 50 mg, about 15 mg to about 50 mg, about 25 mg to about 50 mg, about 50 mg to about 50 mg, about 10 mg to about 50 mg, about 20 mg to about 50 mg, about 30 mg to about 50 mg, or about 40 mg to about 50 mg, about 1 mg to about 45 mg, about 1 mg to about 40 mg, about 2 mg to about 40 mg, about 3 mg to about 40 mg, about 4 mg to about 40 mg, about 5 mg to about 40 mg, about 10 mg to about 40 mg, about 15 mg to about 40 mg, about 20 mg to about 40 mg, about 1 mg to about 35 mg, about 1 mg to about 30 mg, about 1 mg to about 25 mg, about 1 mg to about 20 mg, about 1 mg to about 15 mg, about 2 mg to about 15 mg, about 3 mg to about 15 mg, about 4 mg to about 15 mg, about 5 mg to about 15 mg, about 1 mg to about 10 mg, about 2 mg to about 10 mg, about 3 mg to about 10 mg, about 4 mg to about 10 mg, about 5 mg to about 10 mg, or about 1 mg to about 5 mg. In one embodiment, the amount of seaweed in the composition is about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg. about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg, about 21 mg, about 22 mg. about 23 mg, about 24 mg, about 25 mg, about 26 mg, about 27 mg, about 28 mg, about 29 mg, or about 30 mg.

[0159] In some embodiments, per daily dosage, the composition comprises an enzyme, as disclosed herein, in an amount of about 1 mg to about 300 mg, about 1 mg to about 250 mg. about 1 mg to about 200 mg. about 5 mg to about 200 mg, about 10 mg to about 200 mg, about 15 mg to about 200 mg, about 20 mg to about 200 mg, about 30 mg to about 200 mg, about 40 mg to about 200 mg, about 50 mg to about 200 mg, about 60 mg to about 200 mg, about 70 mg to about 200 mg, about 80 mg to about 200 mg, about 90 mg to about 200 mg, about 100 mg to about 200 mg, about 1 mg to about 150 mg, about 2 mg to about 150 mg, about 3 mg to about 150 mg, about 4 mg to about 150 mg, about 5 mg to about 150 mg, about 1 mg to about 100 mg, about 2 mg to about 100 mg, about 3 mg to about 100 mg. about 4 mg to about 100 mg, about 5 mg to about 100 mg. about 10 mg to about 100 mg, about 15 mg to about 100 mg, about 20 mg to about 100 mg, about 1 mg to about 50 mg, about 1 mg to about 25 mg, about 1 mg to about 10 mg. In one embodiment, the amount of enzyme in the composition is about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg. about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg, about 21 mg, about 22 mg, about 23 mg, about 24 mg, about 25 mg. about 30 mg, about 35 mg, about 40 mg. about 45 mg. about 50 mg. about 55 mg. about 60 mg. about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 180 mg, about 190 mg, about 195 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, or about 300 mg.

[0160] In some embodiments, per daily dosage, the composition comprises an extract, as disclosed herein, in an amount of about 1 mg to about 1500 mg, about 10 mg to about 1500 mg, about 100 mg to about 1500 mg, about 200 mg to about 1500 mg, about 300 mg to about 1500 mg, about 400 mg to about 1500 mg, about 500 mg to about 1500 mg, about 600 mg to about 1500 mg, about 700 mg to about 1500 mg, about 800 mg to about 1500 mg, about 900 mg to about 1500 mg. about 1000 mg to about 1500 mg, about 1 mg to about 1250 mg. about 10 mg to about 1250 mg. about 100 mg to about 1250 mg, about 200 mg to about 1250 mg, about 300 mg to about 1250 mg, about 400 mg to about 1250 mg, about 500 mg to about 1250 mg, about 600 mg to about 1250 mg, about 700 mg to about 1250 mg, about 800 mg to about 1250 mg, about 900 mg to about 1250 mg, about 1000 mg to about 1250 mg, about 1 mg to about 500 mg, about 2 mg to about 500 mg, about 3 mg to about 500 mg, about 4 mg to about 500 mg, about 5 mg to about 500 mg, about 10 mg to about 500 mg, about 100 mg to about 500 mg, about 200 mg to about 500 mg, about 300 mg to about 500 mg, about 400 mg to about 500 mg, about 1 mg to about 200 mg, about 5 mg to about 200 mg, about 10 mg to about 200 mg, about 15 mg to about 200 mg, about 30 mg to about 200 mg. about 40 mg to about 200 mg, about 50 mg to about 200 mg. about 60 mg to about 200 mg, about 70 mg to about 200 mg, about 80 mg to about 200 mg, about 90 mg to about 200 mg, about 100 mg to about 200 mg, about 1 mg to about 150 mg, about 2 mg to about 150 mg, about 3 mg to about 150 mg, about 4 mg to about 150 mg, about 5 mg to about 150 mg, about 10 mg to about 150 mg, about 20 mg to about 150 mg, about 30 mg to about 150 mg, about 40 mg to about 150 mg, about 50 mg to about 150 mg, about 60 mg to about 150 mg, about 1 mg to about 125 mg, about 2 mg to about 125 mg. about 3 mg to about 125 mg, about 4 mg to about 125 mg. about 5 mg to about 125 mg. about 10 mg to about 125 mg, about 30 mg to about 125 mg, about 40 mg to about 125 mg, about 50 mg to about 125 mg, about 60 mg to about 125 mg, about 70 mg to about 125 mg, about 80 mg to about 125 mg, about 90 mg to about 125 mg, about 100 mg to about 125 mg, about 0.1 mg to about 100 mg, about 0.2 mg to about 100 mg, about 0.3 mg to about 100 mg, about 0.4 mg to about 100 mg, about 0.5 mg to about 100 mg, about 1 mg to about 100 mg, about 2 mg to about 100 mg, about 3 mg to about 100 mg. about 4 mg to about 100 mg, about 5 mg to about 100 mg. about 6 mg to about 100 mg. about 7 mg to about 100 mg, about 8 mg to about 100 mg, about 9 mg to about 100 mg, about 10 mg to about 100 mg, about 15 mg to about 100 mg, about 20 mg to about 100 mg, about 30 mg to about 100 mg, about 40 mg to about 100 mg, about 50 mg to about 100 mg, about 60 mg to about 100 mg, about 70 mg to about 100 mg, about 80 mg to about 100 mg, about 90 mg to about 100 mg, about 0.1 mg to about 50 mg, about 0.2 mg to about 50 mg, about 0.3 mg to about 50 mg, about 0.4 mg to about 50 mg, about 0.5 mg to about 50 mg, about 1 mg to about 50 mg, about 2 mg to about 50 mg, about 3 mg to about 50 mg. about 4 mg to about 50 mg. about 5 mg to about 50 mg, about 6 mg to about 50 mg, about 7 mg to about 50 mg, about 8 mg to about 50 mg, about 9 mg to about 50 mg, about 10 mg to about 50 mg, about 30 mg to about 50 mg, about 40 mg to about 50 mg, about 0.1 mg to about 25 mg, about 0.2 mg to about 25 mg, about 0.3 mg to about 25 mg, about 0.4 mg to about 25 mg, about 0.5 mg to about 25 mg, about 1 mg to about 25 mg. about 2 mg to about 25 mg, about 3 mg to about 25 mg, about 4 mg to about 25 mg. about 5 mg to about 25 mg, about 6 mg to about 25 mg, about 7 mg to about 25 mg. about 8 mg to about 25 mg. about 9 mg to about 25 mg, or about 10 mg to about 25 mg. In one embodiment, the amount of extract in the composition is about 0. 1 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg, about 21 mg, about 22 mg, about 23 mg, about 24 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg. about 475 mg, about 500 mg, about 525 mg. about 550 mg, about 575 mg. about 600 mg, about 700 mg. about 800 mg, about 900 mg, about 1000 mg, about 1100 mg, about 1150 mg, about 1200 mg, about 1250 mg, about 1300 mg, about 1350 mg, about 1400 mg, about 1450 mg, or about 1500 mg.

[0161] In some embodiments, per daily dosage, the composition comprises fiber, as disclosed herein, in an amount of about 10 mg to about 6,500 mg. about 10 mg to about 6.400 mg, about 10 mg to about 6,300 mg, about 10 mg to about 6,200 mg, about 10 mg to about 6,100 mg, about 10 mg to about 6,000 mg, about 100 mg to about 6,000 mg, about 110 mg to about 6,000 mg, about 120 mg to about 6,000 mg, about 130 mg to about 6,000 mg, about 140 mg to about 6,000 mg, about 150 mg to about 6,000 mg, about 160 mg to about 6,000 mg, about 170 mg to about 6,000 mg, about 180 mg to about 6,000 mg, about 190 mg to about 6,000 mg, about 200 mg to about 6,000 mg, about 10 mg to about 5,900 mg, about

[0162] 10 mg to about 5,800 mg, about 10 mg to about 5.700 mg. about 10 mg to about 5,600 mg, about 10 mg to about 5,500 mg, about 10 mg to about 5,400 mg, about 10 mg to about 5,300 mg, about 10 mg to about 5,200 mg, about 10 mg to about 5,100 mg, about 10 mg to about 5,000 mg, about 10 mg to about 4,900 mg, about 10 mg to about 4,800 mg, about 10 mg to about 4,700 mg, about 10 mg to about 4,600 mg, about 10 mg to about 4,500 mg, about 10 mg to about 4.400 mg, about 10 mg to about 4,300 mg, about 10 mg to about 4,200 mg, about 10 mg to about 4.100 mg. about 10 mg to about 4,000 mg, about 10 mg to about 3.900 mg, about 10 mg to about 3,800 mg, about 10 mg to about 3.700 mg. about 10 mg to about 3,600 mg, about 10 mg to about 3,500 mg, about 100 mg to about 3,500 mg, about 150 mg to about 3,500 mg, about 200 mg to about 3,500 mg, about 210 mg to about 3,500 mg, about 220 mg to about 3,500 mg, about 230 mg to about 3,500 mg, about 240 mg to about 3,500 mg, about 250 mg to about 3,500 mg, about 260 mg to about 3,500 mg, about 270 mg to about 3,500 mg, about 280 mg to about 3,500 mg, about 290 mg to about 3,500 mg, about 300 mg to about 3,500 mg, about 10 mg to about 3,400 mg, about

[0163] 10 mg to about 3,300 mg, about 10 mg to about 3,200 mg, about 10 mg to about 3,100 mg, about 10 mg to about 3,000 mg, about 10 mg to about 2,500 mg, about 10 mg to about 2,000 mg, about 10 mg to about 1,500 mg, about 10 mg to about 1,000 mg, about 10 mg to about 900 mg, about 10 mg to about 800 mg, about 10 mg to about 700 mg, about 10 mg to about 600 mg, about 10 mg to about 500 mg, about 10 mg to about 400 mg, about 10 mg to about 300 mg, about 10 mg to about 200 mg, or about 10 mg to about 100 mg. In one embodiment, the amount of fiber in the composition is about 5 mg, about 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 145 mg, about 150 mg, about

[0164] 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about

[0165] 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about

[0166] 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg. about 550 mg, about 600 mg, about

[0167] 650 mg. about 700 mg, about 710 mg. about 720 mg, about 730 mg. about 740 mg, about 750 mg, about

[0168] 800 mg, about 850 mg, about 900 mg, about 1,000 mg, about 1,100 mg, about 1,200 mg, about 1,300 mg, about 1,400 mg, about 1,500 mg, about 1,600 mg, about 1,700 mg, about 1,800 mg, about 1,900 mg, about 2,000 mg, about 2,500 mg, about 3,000 mg, about 3,500 mg, about 4,000 mg, about 4,500 mg, about 5,000 mg, about 5,500 mg, about 6,000 mg, or about 6,500 mg.

[0169] In some embodiments, per daily dosage, the composition comprises microalgae, as disclosed herein, in an amount of about 10 mg to about 5,500 mg, about 10 mg to about 5,400 mg, about 10 mg to about 5,300 mg, about 10 mg to about 5,200 mg, about 10 mg to about 5,100 mg, about 10 mg to about 5,000 mg, about 100 mg to about 5,000 mg, about 110 mg to about 5,000 mg, about 120 mg to about

[0170] 5,000 mg, about 130 mg to about 5,000 mg, about 140 mg to about 5,000 mg, about 150 mg to about

[0171] 5,000 mg. about 160 mg to about 5,000 mg. about 170 mg to about 5,000 mg. about 180 mg to about

[0172] 5,000 mg, about 190 mg to about 5,000 mg, about 200 mg to about 5,000 mg, about 210 mg to about

[0173] 5,000 mg, about 220 mg to about 5,000 mg, about 230 mg to about 5,000 mg, about 240 mg to about

[0174] 5,000 mg, about 250 mg to about 5,000 mg, about 260 mg to about 5,000 mg, about 270 mg to about

[0175] 5,000 mg, about 280 mg to about 5,000 mg, about 290 mg to about 5,000 mg, about 300 mg to about

[0176] 5,000 mg, about 10 mg to about 4.900 mg, about 10 mg to about 4,800 mg, about 10 mg to about 4,700 mg, about 10 mg to about 4.600 mg. about 10 mg to about 4,500 mg, about 10 mg to about 4.400 mg. about 10 mg to about 4,300 mg, about 10 mg to about 4,200 mg, about 10 mg to about 4, 100 mg, about 10 mg to about 4,000 mg, about 10 mg to about 3,900 mg, about 10 mg to about 3,800 mg, about 10 mg to about 3,700 mg, about 10 mg to about 3,600 mg, about 10 mg to about 3,500 mg, about 10 mg to about 3,400 mg, about 10 mg to about 3.300 mg, about 10 mg to about 3,200 mg, about 10 mg to about 3,100 mg, about 10 mg to about 3.000 mg. about 10 mg to about 2,500 mg, about 10 mg to about 2,000 mg, about 10 mg to about 1,500, mg, about 10 mg to about 1,000 mg, about 20 mg to about 1,000 mg, about 30 mg to about 1,000 mg, about 40 mg to about 1,000 mg, about 50 mg to about 1,000 mg, about 60 mg to about 1,000 mg, about 70 mg to about 1,000 mg, about 80 mg to about 1,000 mg, about 90 mg to about 1,000 mg, about 100 mg to about 1,000 mg, about 10 mg to about 900 mg, about 10 mg to about 800 mg, about 10 mg to about 700 mg, about 10 mg to about 600 mg, about 10 mg to about 500 mg, about 50 mg to about 500 mg, about 0.2 mg to about 20 mg, about 0.2 mg to about 15 mg, about 0.2 mg to about 10 mg, about 0.5 mg to about 10 mg, about 1 mg to about 10 mg, about 2 mg to about 10 mg, or about 5 mg to about 10 mg. In one embodiment, the amount of microalgae in the composition is about 0.1 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg. about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg. about 160 mg, about 170 mg. about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 550 mg, about 600 mg, about 650 mg, about 700 mg, about 750 mg, about 800 mg, about 850 mg, about 900 mg, about 1,000 mg, about 1,100 mg, about 1,200 mg, about 1,300 mg, about 1,400 mg, about 1,500 mg, about 1,600 mg, about 1,700 mg, about 1,800 mg, about 1,900 mg, about 2,000 mg, about 2,500 mg, about 3,000 mg. about 3,500 mg, about 4,000 mg. about 4,500 mg, about 5,000 mg. about 5,500 mg, about 6,000, or about 6,500 mg.

[0177] In some embodiments, per daily dosage, the composition comprises a micronutrient, as disclosed herein, in an amount of about 1 mg to about 400 mg, about 5 mg to about 400 mg. about 10 mg to about 400 mg. about 15 mg to about 400 mg, about 20 mg to about 400 mg. about 25 mg to about 400 mg, about 30 mg to about 400 mg, about 40 mg to about 400 mg, about 50 mg to about 400 mg, about 75 mg to about 400 mg, about 100 mg to about 400 mg, about 1 mg to about 350 mg, about 1 mg to about 300 mg, about 5 mg to about 300 mg, about 10 mg to about 300 mg, about 15 mg to about 300 mg, about 16 mg to about 300 mg, about 17 mg to about 300 mg, about 18 mg to about 300 mg. about 19 mg to about 300 mg, about 20 mg to about 300 mg, about 21 mg to about 300 mg, about 22 mg to about 300 mg, about 23 mg to about 300 mg. about 24 mg to about 300 mg, about 25 mg to about 300 mg. about 30 mg to about 300 mg, about 40 mg to about 200 mg, about 50 mg to about 300 mg, about 75 mg to about 300 mg, about 100 mg to about 300 mg, about 125 mg to about 300 mg, about 1 mg to about 250 mg, about 5 mg to about 250 mg, about 10 mg to about 250 mg, about 15 mg to about 250 mg, about 16 mg to about 250 mg, about 17 mg to about 250 mg, about 18 mg to about 250 mg, about 19 mg to about 250 mg, about 20 mg to about 250 mg, about 21 mg to about 250 mg, about 22 mg to about 250 mg, about 23 mg to about 250 mg, about 24 mg to about 250 mg, about 25 mg to about 250 mg, about 1 mg to about 200 mg, about 5 mg to about 200 mg, about 10 mg to about 200 mg, about 11 mg to about 200 mg, about 12 mg to about 200 mg, about 13 mg to about 200 mg, about 14 mg to about 200 mg, about 15 mg to about 200 mg, about 20 mg to about 200 mg, about 30 mg to about 200 mg, about 40 mg to about 200 mg, about 50 mg to about 200 mg, about 60 mg to about 200 mg, about 70 mg to about 200 mg, about 80 mg to about 200 mg, about 90 mg to about 200 mg, about 100 mg to about 200 mg, about 110 mg to about 200 mg, about 1 mg to about 150 mg, about 2 mg to about 150 mg, about 3 mg to about 150 mg, about 4 mg to about 150 mg, about 5 mg to about 150 mg, about 1 mg to about 100 mg, about 2 mg to about 100 mg, about 3 mg to about 100 mg, about 4 mg to about 100 mg, about 5 mg to about 100 mg, about 6 mg to about 100 mg, about 7 mg to about 100 mg, about 8 mg to about 100 mg, about 9 mg to about 100 mg, about 10 mg to about 100 mg, about 15 mg to about 100 mg, about 20 mg to about 100 mg, about 25 mg to about 100 mg, about 30 mg to about 100 mg, about 1 mg to about 50 mg. about 5 mg to about 50 mg. or about 10 mg to about 50 mg. In one embodiment, the amount of micronutrient in the composition is about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg, about 21 mg, about 22 mg, about 23 mg, about 24 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg. about 60 mg, about 70 mg, about 80 mg. about 90 mg. about 100 mg, about 105 mg. about 110 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, or about 400 mg.

[0178] In some embodiments, per daily dosage, the composition comprises a mineral, as disclosed herein, in an amount of about 1 mg to about 600 mg, about 10 mg to about 600 mg, about 15 mg to about 600 mg, about 20 mg to about 600 mg, about 25 mg to about 600 mg, about 30 mg to about 600 mg, about 40 mg to about 600 mg, about 45 mg to about 600 mg, about 50 mg to about 600 mg, about 1 mg to about 550 mg, about 10 mg to about 550 mg, about 15 mg to about 550 mg, about 20 mg to about 550 mg, about 25 mg to about 550 mg, about 30 mg to about 550 mg, about 40 mg to about 550 mg, about 45 mg to about 550 mg, about 50 mg to about 550 mg, about 1 mg to about 300 mg, about 10 mg to about 300 mg. about 15 mg to about 300 mg, about 20 mg to about 300 mg. about 25 mg to about 300 mg, about 30 mg to about 300 mg, about 40 mg to about 300 mg, about 45 mg to about 300 mg, about 50 mg to about 300 mg, about 1 mg to about 150 mg, about 1 mg to about 125 mg, about 5 mg to about 125 mg, about 10 mg to about 125 mg, about 20 mg to about 125 mg, about 1 mg to about 120 mg, about 1 mg to about 110 mg, about 0.01 mg to about 100 mg, about 0.02 mg to about 100 mg, about 0.03 mg to about 100 mg, about 0.04 mg to about 100 mg, about 0.05 mg to about 100 mg, about 0.1 mg to about 100 mg, about 0.2 mg to about 100 mg, about 0.3 mg to about 100 mg, about 0.4 mg to about 100 mg, about 0.5 mg to about 100 mg, about 1 mg to about 100 mg, about 5 mg to about 100 mg, about 6 mg to about 100 mg, about 7 mg to about 100 mg, about 8 mg to about 100 mg, about 9 mg to about 100 mg, about 10 mg to about 100 mg, about 15 mg to about 100 mg, about 20 mg to about 100 mg, about 25 mg to about 100 mg, about 30 mg to about 100 mg, about 35 mg to about 100 mg, about 40 mg to about 100 mg, about 45 mg to about 100 mg, about 50 mg to about 100 mg, about 1 mg to about 50 mg, about 2 mg to about 50 mg, about 3 mg to about 50 mg, about 4 mg to about 50 mg, about 5 mg to about 50 mg, about 6 mg to about 50 mg, about 7 mg to about 50 mg, about 8 mg to about 50 mg, about 9 mg to about 50 mg, about 10 mg to about 50 mg, about 15 mg to about 50 mg, about 20 mg to about 50 mg, about 25 mg to about 50 mg, about 1 mg to about 20 mg, about 2 mg to about 20 mg, about 3 mg to about 20 mg, about 4 mg to about 20 mg, about 5 mg to about 20 mg, about 0.001 mg to about 2 mg, about 0.005 mg to about 2 mg. about 0.006 mg to about 2 mg, about 0.007 mg to about 2 mg. about 0.008 mg to about 2 mg, about 0.009 mg to about 2 mg, about 0.01 mg to about 2 mg, about 0.02 mg to about 2 mg, about 0.03 mg to about 2 mg, about 0.04 mg to about 2 mg, about 0.05 mg to about 2 mg, about 0.06 mg to about 2 mg, about 0.07 mg to about 2 mg, about 0.07 mg to about 2 mg, about 0.08 mg to about 2 mg, about 0.09 mg to about 2 mg, about 0.1 mg to about 2 mg, about 0.001 mg to about 1 mg, about 0.005 mg to about 1 mg, about 0.006 mg to about 1 mg. about 0.007 mg to about 1 mg, about 0.008 mg to about 1 mg, about 0.009 mg to about 1 mg, about 0.01 mg to about 1 mg. about 0.02 mg to about 1 mg. about 0.03 mg to about 1 mg. about 0.04 mg to about 1 mg, about 0.05 mg to about 1 mg, about 0.06 mg to about 1 mg, about 0.07 mg to about 1 mg, about 0.07 mg to about 1 mg, about 0.08 mg to about 1 mg, about 0.09 mg to about 1 mg, about 0. 1 mg to about 1 mg, about 0.001 mg to about 0.5 mg, about 0.005 mg to about 0.5 mg, about 0.006 mg to about 0.5 mg, about 0.007 mg to about 0.5 mg, about 0.008 mg to about 0.5 mg, about 0.009 mg to about 0.5 mg, about 0.01 mg to about 0.5 mg. about 0.02 mg to about 0.5 mg. about 0.03 mg to about 0.5 mg, about 0.04 mg to about 0.5 mg, about 0.05 mg to about 0.5 mg. about 0.06 mg to about 0.5 mg, about 0.07 mg to about 0.5 mg, about 0.07 mg to about 0.5 mg, about 0.08 mg to about 0.5 mg, about 0.09 mg to about 0.5 mg, about 0.1 mg to about 0.5 mg, about 0.2 mg to about 0.5 mg, about 0.001 mg to about 0.2 mg, about 0.005 mg to about 0.2 mg, about 0.006 mg to about 0.2 mg, about 0.007 mg to about 0.2 mg, about 0.008 mg to about 0.2 mg, about 0.009 mg to about 0.2 mg, about 0.01 mg to about 0.2 mg, about 0.02 mg to about 0.2 mg, about 0.03 mg to about 0.2 mg, about 0.04 mg to about 0.2 mg, about 0.05 mg to about 0.2 mg, about 0.06 mg to about 0.2 mg, about 0.07 mg to about 0.2 mg, about 0.07 mg to about 0.2 mg, about 0.08 mg to about 0.2 mg, about 0.09 mg to about 0.2 mg, about 0.1 mg to about 0.2 mg, about 0.001 mg to about 0.1 mg, about 0.005 mg to about 0.1 mg, about 0.006 mg to about 0.1 mg, about 0.007 mg to about 0.1 mg, about 0.008 mg to about 0.1 mg, about 0.009 mg to about 0.1 mg, about 0.01 mg to about 0.1 mg, about 0.02 mg to about 0.1 mg, about 0.03 mg to about 0.1 mg, about 0.04 mg to about 0.1 mg, about 0.05 mg to about 0.1 mg, about 0.001 mg to about 0.05 mg, about 0.005 mg to about 0.05 mg, about 0.006 mg to about 0.05 mg. about 0.007 mg to about 0.05 mg, about 0.008 mg to about 0.05 mg, about 0.009 mg to about 0.05 mg, about 0.01 mg to about 0.05 mg, about 0.02 mg to about 0.05 mg, or about 0.03 mg to about 0.05 mg. In one embodiment, the amount of minerals in the composition is about 0.001 mg, about 0.002 mg, about 0.003 mg, about 0.004 mg, about 0.005 mg, about 0.006 mg, about 0.007 mg, about 0.008 mg, about 0.009 mg, about 0.01 mg, about 0.02 mg, about 0.03 mg, about 0.04 mg, about 0.05 mg, about 0.06 mg, about 0.07 mg, about 0.08 mg, about 0.09 mg, about 0.1 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg, about 21 mg, about 22 mg, about 23 mg, about 24 mg, about 25 mg, about 26 mg. about 27 mg, about 28 mg, about 29 mg. about 30 mg. about 35 mg. about 40 mg, about 41 mg, about 42 mg, about 43 mg, about 44 mg, about 45 mg, about 50 mg, about 60 mg, about 65 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 175 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 275 mg, about 280 mg, about 290 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 550 mg, about 600 mg, about 650 mg, or about 700 mg.

[0179] In some embodiments, per daily dosage, the composition comprises a probiotic, as disclosed herein, in an amount of about 2B CFU to about 50B CFU, about 3B CFU to about 50B CFU, about 4B CFU to about 50B CFU. about 5B CFU to about 50B CFU, about 6B CFU to about 50B CFU, about 7B CFU to about 50B CFU. about 8B CFU to about 50B CFU, about 9B CFU to about 50B CFU, about 10B CFU to about 50B CFU, about 1 IB CFU to about 50B CFU, about 12B CFU to about 50B CFU, about 13B CFU to about 50B CFU, about 14B CFU to about 50B CFU, about 15B CFU to about 50B CFU, about 20B CFU to about 50B CFU, about 30B CFU to about 50B CFU, about 35B CFU to about 50B CFU, about 2B CFU to about 40B CFU. about 3B CFU to about 40B CFU, about 4B CFU to about 40B CFU, about 5B CFU to about 40B CFU. about 6B CFU to about 40B CFU, about 7B CFU to about 40B CFU, about 8B CFU to about 40B CFU. about 9B CFU to about 40B CFU, about 10B CFU to about 40B CFU, about 1 IB CFU to about 40B CFU, about 12B CFU to about 40B CFU, about 13B CFU to about 40B CFU, about 14B CFU to about 40B CFU, about 15B CFU to about 40B CFU, about 20B CFU to about 40B CFU, about 30B CFU to about 40B CFU, about 35B CFU to about 40B CFU, about 2B CFU to about 30B CFU, about 2B CFU to about 20B CFU, about 2B CFU to about 15B CFU, about 2B CFU to about 14B CFU, about 2B CFU to about 13B CFU, about 2B CFU to about 12B CFU, about 2B CFU to about 1 IB CFU, about 2B CFU to about 10B CFU, about 2B CFU to about 9B CFU, or about 2B CFU to about 8B CFU. In one embodiment, the amount of the probiotic in the composition is about 2B CFU, about 3B CFU, about 4B CFU, about 5B CFU, about 6B CFU, about 7B CFU, about 8B CFU, about 9B CFU, about 10B CFU, about 1 IB CFU, about 12B CFU, about 13B CFU, about 14B CFU, about 15B

[0180] CFU, about 16B CFU. about 17B CFU, about 18B CFU, about 19B CFU, about 20B CFU, about 25B

[0181] CFU, about 30B CFU. about 35B CFU, about 40B CFU, about 45B CFU. or about 50B CFU. In some embodiments, per daily dosage, the composition comprises a protein, as disclosed herein, in an amount of about 150 mg to about 25,000 mg, about 180 mg to about 25,000 mg, about 180 mg to about 20,000 mg, about 180 mg to about 15,000 mg, about 180 mg to about 10,000 mg, about 180 mg to about 5,000 mg, about 180 mg to about 1,200 mg, about 180 mg to about 1,100 mg, about 180 mg to about 1,000 mg, about 180 mg to about 900 mg. about 180 mg to about 800 mg. about 180 mg to about 700 mg. about 180 mg to about 600 mg. about 180 mg to about 500 mg. about 200 mg to about 25,000 mg, about 250 mg to about 25,000 mg, about 300 mg to about 25,000 mg, about 350 mg to about 25,000 mg, about 400 mg to about 25,000 mg, about 450 mg to about 25,000 mg, about 500 mg to about 25,000 mg, about 550 mg to about 25,000 mg, about 600 mg to about 25,000 mg, about 650 mg to about 25,000 mg, about 700 mg to about 25,000 mg, about 750 mg to about 25,000 mg, about 850 mg to about 25,000 mg, about 900 mg to about 25,000 mg, about 950 mg to about 25,000 mg, about 1,000 mg to about 25,000 mg, about 1,500 mg to about 25.000 mg. about 2,000 mg to about 25,000 mg, about 3.000 mg to about 25,000 mg, about 4,000 mg to about 25,000 mg, about 5,000 mg to about 25,000 mg, or about 10,000 mg to about 25,000 mg. In one embodiment, the amount of protein in the composition is about

[0182] 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 250 mg, about

[0183] 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 550 mg, about 600 mg, about

[0184] 650 mg, about 700 mg, about 750 mg. about 800 mg, about 850 mg. about 900 mg, about 925 mg, about

[0185] 950 mg. about 975 mg, about 1.000 mg. about 1,100 mg, about 1,200 mg. about 1,300 mg, about 1,400 mg, about 1,500 mg, about 2,000 mg, about 2,500 mg, about 3,000 mg, about 3,500 mg, about 4,000 mg, about 5,000 mg, about 6,000 mg, about 7,000 mg, about 8,000 mg, about 9,000 mg, about 10,000 mg, about 15,000 mg, about 20,000 mg, about 25,000 mg, or about 30,000 mg.

[0186] In some embodiments, per daily dosage, the composition comprises a vitamin, as disclosed herein, in an amount of about 0.0001 mg to about 2,000 mg, about 0.001 mg to about 2,000 mg, about 0.01 mg to about 2,000 mg, about 0.02 mg to about 2,000 mg, about 0.03 mg to about 2,000 mg, about 0.04 mg to about 2,000 mg, about 0.06 mg to about 2,000 mg, about 0.08 mg to about 2,000 mg, about 0.1 mg to about 2,000 mg. about 0.2 mg to about 2,000 mg, about 0.3 mg to about 2,000 mg, about 0.4 mg to about 2.000 mg, about 0.5 mg to about 2,000 mg, about 0.6 mg to about 2,000 mg, about 0.8 mg to about 2,000 mg, about 1 mg to about 2,000 mg, about 100 mg to about 1,500 mg, about 100 mg to about 1,250 mg, about 100 mg to about 1,000 mg, about 100 mg to about 750 mg, about 100 mg to about 500 mg, about 1 mg to about 270 mg, about 5 mg to about 270 mg, about 10 mg to about 270 mg, about 1 mg to about 250 mg, about 5 mg to about 250 mg, about 10 mg to about 250 mg, about 1 mg to about 200 mg, about 5 mg to about 200 mg, about 10 mg to about 200 mg, about 20 mg to about 200 mg, about 30 mg to about 200 mg, about 35 mg to about 200 mg, about 40 mg to about 200 mg. about 45 mg to about 200 mg, about 50 mg to about 200 mg, about 0.8 mg to about 50 mg, about 1 mg to about 50 mg, about 2 mg to about 50 mg, about 3 mg to about 50 mg, about 4 mg to about 50 mg, about 5 mg to about 50 mg, about 6 mg to about 50 mg, about 10 mg to about 50 mg, about 15 mg to about 50 mg, about 16 mg to about 50 mg, about 17 mg to about 50 mg, about 18 mg to about 50 mg, about 19 mg to about 50 mg, about 20 mg to about 50 mg, about 1 mg to about 25 mg, about 2 mg to about 25 mg, about 3 mg to about 25 mg, about 4 mg to about 25 mg, about 5 mg to about 25 mg, about 6 mg to about 25 mg, about 7 mg to about 25 mg, about 1 mg to about 20 mg, about 2 mg to about 20 mg, about 3 mg to about 20 mg, about 4 mg to about 20 mg, about 5 mg to about 20 mg, about 6 mg to about 20 mg, about 7 mg to about 20 mg, about 8 mg to about 20 mg, about 9 mg to about 20 mg, about 10 mg to about 20 mg, about 1 mg to about 15 mg, about 2 mg to about 15 mg, about 3 mg to about 15 mg, about 4 mg to about 15 mg, about 5 mg to about 15 mg, about 6 mg to about 15 mg, about 7 mg to about 15 mg, about 8 mg to about 15 mg, about 9 mg to about 15 mg, about 10 mg to about 15 mg, about 0.02 mg to about 10 mg, about 0.05 mg to about 10 mg, about 0. 1 mg to about 10 mg, about 0.2 mg to about 10 mg, about 0.4 mg to about 10 mg, about 0.6 mg to about 10 mg, about 0.8 mg to about 10 mg, about 1 mg to about 10 mg, about 2 mg to about 10 mg, about 3 mg to about 10 mg, about 0.6 mg to about 8 mg, about 0.6 mg to about 7 mg, about 1 mg to about 7 mg, about 2 mg to about 7 mg, about 1 mg to about 6 mg, about 2 mg to about 6 mg, about 0.4 mg to about 5 mg. about 0.3 mg to about 4 mg, about 0.8 mg to about 4 mg, about 0.3 mg to about 3 mg, about 0.5 mg to about 3 mg. about 0.6 mg to about 3 mg, about 1 mg to about 3 mg. about 2 mg to about 3 mg, about 0.08 mg to about 2 mg, about 0.09 mg to about 2 mg, about 0.1 mg to about 2 mg, about 0.2 mg to about 2 mg, about 0.3 mg to about 2 mg, about 0.4 mg to about 2 mg, about 0.5 mg to about 2 mg, about 0.6 mg to about 2 mg, about 0.7 mg to about 2 mg, about 0.08 mg to about 1 mg, about 0.09 mg to about 1 mg, about 0.1 mg to about 1 mg, about 0.2 mg to about 1 mg, about 0.3 mg to about 1 mg, about 0.4 mg to about 1 mg, about 0.5 mg to about 1 mg, about 0.06 mg to about 0.9 mg, about 0.06 mg to about 0.8 mg, about 0.07 mg to about 0.9 mg, about 0.07 mg to about 0.8 mg. about 0.1 mg to about 0.5 mg, about 0.02 mg to about 0.3 mg, about 0.03 mg to about 0.3 mg, about 0.04 mg to about 0.3 mg, about 0.05 mg to about 0.3 mg, about 0.06 mg to about 0.3 mg, or about 0.02 mg to about 0.2 mg. In one embodiment, the amount of a vitamin in the composition is about 0.0001 mg, about 0.01 mg, about 0.02 mg, about 0.03 mg, about 0.04 mg, about 0.05 mg, about 0.06 mg, about 0.07 mg, about 0.08 mg, about 0.09 mg, about 0.1 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg. about 0.9 mg, about 1 mg, about 2 mg, about 3 mg. about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 41 mg, about 42 mg, about 43 mg, about 44 mg, about 45 mg, about 50 mg, about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg. about 225 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1,000 mg, about 1,250 mg, about 1,500 mg, about 1,750 mg, or about 2,000 mg.

[0187] In some embodiments, per daily dosage, the composition comprises a whole fruit or vegetable powder, as disclosed herein, in an amount of about 5 mg to about 3,000 mg, about 10 mg to about 3,000 mg, about 20 mg to about 3,000 mg, about 30 mg to about 3,000 mg, about 40 mg to about 3,000 mg, about 50 mg to about 3,000 mg, about 60 mg to about 3,000 mg, about 240 mg to about 3,000 mg, about 5 mg to about 2,500 mg. about 10 mg to about 2,500 mg, about 20 mg to about 2,500 mg, about 30 mg to about 2,500 mg, about 40 mg to about 2,500 mg, about 50 mg to about 2,500 mg, about 60 mg to about

[0188] 2.500 mg. about 500 mg to about 2,500 mg. about 5 mg to about 2,000 mg, about 10 mg to about 2.000 mg, about 20 mg to about 2,000 mg, about 30 mg to about 2,000 mg, about 40 mg to about 2,000 mg, about 50 mg to about 2,000 mg, about 60 mg to about 2,000 mg, about 750 mg to about 2,000 mg, about 5 mg to about 1,500 mg, about 10 mg to about 1,500 mg, about 20 mg to about 1,500 mg, about 30 mg to about 1,500 mg, about 40 mg to about 1,500 mg, about 50 mg to about 1,500 mg, about 60 mg to about

[0189] 1.500 mg, about 1,000 mg to about 1,500 mg, about 5 mg to about 1,000 mg, about 10 mg to about 1,000 mg, about 20 mg to about 1.000 mg. about 30 mg to about 1,000 mg, about 40 mg to about 1,000 mg. about 50 mg to about 1 ,000 mg, about 60 mg to about 1 ,000 mg, about 5 mg to about 750 mg, about 10 mg to about 750 mg, about 20 mg to about 750 mg, about 30 mg to about 750 mg, about 40 mg to about 750 mg, about 50 mg to about 750 mg, about 60 mg to about 750 mg, about 5 mg to about 500 mg, about 10 mg to about 500 mg, about 20 mg to about 500 mg, about 30 mg to about 500 mg, about 40 mg to about 500 mg. about 50 mg to about 500 mg, about 60 mg to about 500 mg, about 5 mg to about 400 mg, about 10 mg to about 400 mg. about 15 mg to about 400 mg, about 20 mg to about 400 mg. about 30 mg to about 400 mg, about 40 mg to about 400 mg, about 50 mg to about 400 mg, about 60 mg to about 400 mg, about 70 mg to about 400 mg, about 80 mg to about 400 mg, about 5 mg to about 350 mg, about 10 mg to about 350 mg, about 20 mg to about 350 mg, about 30 mg to about 350 mg, about 40 mg to about 350 mg, about 50 mg to about 350 mg, about 60 mg to about 350 mg, about 70 mg to about 350 mg, about 80 mg to about 350 mg, about 5 mg to about 300 mg, about 10 mg to about 300 mg, about 20 mg to about 300 mg, about 30 mg to about 300 mg, about 40 mg to about 300 mg, about 50 mg to about 300 mg, about 60 mg to about 300 mg, about 70 mg to about 300 mg, about 80 mg to about 300 mg, about 5 mg to about 250 mg, about 10 mg to about 250 mg, about 20 mg to about 250 mg, about 30 mg to about 250 mg, about 40 mg to about 250 mg, about 50 mg to about 250 mg, about 60 mg to about 250 mg, about 5 mg to about 200 mg, about 10 mg to about 200 mg, about 15 mg to about 200 mg, about 20 mg to about 200 mg. about 30 mg to about 200 mg, about 40 mg to about 200 mg, about 50 mg to about 200 mg, about 60 mg to about 200 mg, about 5 mg to about 100 mg, about 10 mg to about 100 mg, about 15 mg to about 100 mg, about 20 mg to about 100 mg, about 30 mg to about 100 mg, about 40 mg to about 100 mg, about 50 mg to about 100 mg, about 60 mg to about 100 mg, about 5 mg to about 80 mg, about 10 mg to about 80 mg, about 15 mg to about 80 mg, about 20 mg to about 80 mg, about 30 mg to about 80 mg, about 40 mg to about 80 mg. about 5 mg to about 50 mg, about 10 mg to about 50 mg. about 15 mg to about 50 mg, or about 20 mg to about 50 mg. In one embodiment, the amount of the whole fruit or vegetable in the composition is about 1 mg, about 5mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 15 mg, 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg, about 25 mg, about 30 mg, about 31 mg, about 32 mg, about 33 mg, about 34 mg, about 35 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 230 mg. about 235 mg, about 240 mg, about 245 mg, about 250 mg, about 260 mg. about 270 mg, about 280 mg. about 290 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 550 mg, about 600 mg, about 650 mg, about 700 mg, about 750 mg, about 800 mg, about 900 mg, about 1,000 mg, about 1,100 mg, about 1,200 mg, about 1,300 mg, about 1,400 mg, about 1,500 mg, about 1,750 mg, about 2,000 mg, about 2,500 mg, or about 3,000 mg.

[0190] In various embodiments, the compositions disclosed herein may comprise one or more excipients. The excipients include those described above, such as bulking agents, binding agents, disintegrants, preservatives, antioxidants, coloring agents, flavoring agents, sweetening agents, taste masking agents, stabilizers, and any combination thereof.

[0191] In some embodiments, the composition comprises a flavoring agent. The flavoring agent may be selected from eucalyptus, vanilla, citrus oil, lemon oil, orange oil, grape oil, grapefruit oil, citric acid, and fruit essences including apple, peach, pear, strawberry , raspberry, cherry, plum, pineapple, and apricot and any combination thereof.

[0192] In another embodiment, the composition comprises a sweetening agent. The sweetening agent may be selected from as sucrose, lactose, glucose, fructose, reduced glucose, maltose, xylitol, maltitol, sorbitol, mannitol, lactitol, isomalt, erythritol, polyglycitol, polyglucitol, glycerol, stevia, agave nectar, inverti syrup, maltodcxtrin. monkfruit, monkfruit extract, allulose, sucralose, aspartame, acesulfame potassium (or Ace-K). advantame. ethyl maltol, neotame, trehalose, raffinose, cellobiose, tagatose, inulin. N-[N-[3-(3-hydroxy-4-methoxyphenyl)propyl]-alpha-aspartyl]-L-phenylalanine 1-methyl ester, glycyrrhizin, sodium cyclamate, brazzein, miraculin, curculin, pentadin, mabinlin, NHDC, thaumatin, naringin dihydrochalcone, and combinations thereof. In some embodiments, the excipient comprises one or more fats or oils. Suitable fats and oils include lecithin, soy lecithin, sunflower lecithin, egg yok lecithin, canola lecithin, algal oil, peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil, soybean oil, and combinations thereof.

[0193] 3.3 NUTRACEUTICAL COMPOSITIONS

[0194] In various embodiments, a composition of the disclosure is a nutraceutical composition and further comprises a nutraceutically acceptable carrier. Tire nutraceutically acceptable carrier include those described above, such as, bulking agents, binding agents, disintegrants, preservatives, antioxidants, coloring agents, flavoring agents, sweetening agents, taste masking agents, stabilizers, fats, oils, and any combination thereof. In some embodiments, the nutraceutical composition comprises one or more flavoring agents. The flavoring agent may be selected from eucalyptus, vanilla, citrus oil, lemon oil, orange oil, grape oil, grapefruit oil, citric acid, fruit flavorings, and fruit essences including apple, peach, pear, strawberry, raspberry, cherry, plum, pineapple, and apricot.

[0195] In another embodiment, the nutraceutical composition comprises a sweetening agent. The sweetening agent may be selected from as sucrose, lactose, glucose, fructose, reduced glucose, maltose, xylitol, maltitol, sorbitol, mannitol, lactitol, isomalt, erythritol, polyglycitol, polyglucitol, glycerol, stevia, Stevia leaf extract, glycosides and rebaudiosides A, B, and M. agave nectar, inverti syrup, maltodextrin, monkfruit, monkfruit extract, allulose, sucralose, aspartame, acesulfame potassium (or Ace-K), advantame, ethyl maltol, neotame, trehalose, raffinose, cellobiose, tagatose, inulin, N-[N-[3-(3-hydroxy- 4-methoxyphenyl)propyl] -alpha-aspartyl] -L-phenylalanine 1 -methyl ester, glycyrrhizin, sodium cyclamate, brazzein, miraculin, curculin, pentadin, mabinlin, NHDC, thaumatin, naringin dihydrochalcone, and combinations thereof.

[0196] In some embodiments, the nutraceutical composition comprises one or more fats or oils. Suitable fats and oils include lecithin, soy lecithin, sunflower lecithin, egg yok lecithin, canola lecithin, algal oil, peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil, soybean oil, and combinations thereof.

[0197] 3.4 DOSAGE FORMS

[0198] The compositions disclosed herein may be an oral dosage form and intended to be administered orally to a subject. The oral dosage form may be classified as a food additive, dietary supplement, or a nutraceutical. In various embodiments, the compositions disclosed herein can be formulated for oral administration in liquid dosage form. Examples of suitable liquid dosage forms include solutions or suspensions in water or a water-based liquid, such as fruit juice, plant-based milks (oat milk, almond milk, soy milk, coconut milk, rice milk, cashew milk, hemp milk, pea milk, and hazelnut milk), coconut water, aloe vera juice, cactus water, maple water, birch water, watennelon water, cucumber water, pineapple water, and combinations thereof.

[0199] In various embodiments, compositions disclosed herein can be formulated for oral administration in a solid dosage form. Tire solid dosage form may be a tablet, a capsule, a granule, or a powder. In some embodiments, a solid dosage fonn can be incorporated into a food, food product, or beverage. For example, the solid dosage composition can be incorporated into a food, food product, or beverage selected from water, water-based liquids, milk, milk-based liquids, plant-based milks, coffee, tea, fruit juice, fruit drink, fruit blend, sports drink, smoothie, protein shake, energy drink, yogurt, yogurt blend, snack bar, energy bar, cookie, brownie, muffin, cracker, biscuit, and cereal or chocolate bar.

[0200] 3.5 PREPARATION OF THE COMPOSITIONS

[0201] Tire compositions disclosed herein can be prepared according to methods known in the art. In some embodiments, the composition can be prepared by (a) mixing each of adaptogens, botanicals, seaweeds, enzymes, extracts, fibers, microalgae, micronutrients, minerals, protein, vitamins, and whole fruit or vegetable powders: and (b) combining probiotics with the mixture from step (a) to generate a powder blend. The amounts and ratios of the various ingredients used in step (a) and step (b) are as described in Sections 3.2 and 3.3.

[0202] In some aspects of this embodiment, step (a) comprises mixing one or more of each of adaptogens, botanicals, seaweeds, enzymes, extracts, fibers, microalgae, micronutrients, minerals, protein, vitamins, and whole fruit or vegetable powders.

[0203] In some aspects of this embodiment, step (b) comprises combining three or more of probiotics with the mixture from step (a) to generate a powder blend.

[0204] In various embodiments, the step (b) comprises combining an excipient with the mixture from step (a). In other embodiments, the step (b) comprises combining a nutrace utically acceptable carrier with the mixture from step (a).

[0205] Tire composition of the disclosure can be filled into a dose packet, travel pack, pouch, sachet, bottle, stick-pack, or the like. Tire contents of the dose packet, travel pack, pouch, sachet, bottle, stick- pack, or the like can be emptied into a food, food product, or beverage, as defined in Section 3.4, at a time for oral administration.

[0206] 3.6 ADMINISTRATION, REGIMENS AND DOSE LEVELS

[0207] The compositions disclosed herein can be presented in unit dosage forms, single dose form, or daily dose form. The dose fonns may be a packaged formulation (such as, a dose packet, travel pack, pouch, sachet, bottle, stick-pack or the like), the package containing the desired amount of the composition of the disclosure.

[0208] When a composition disclosed herein is administered, the dosage is expressed based on the amount of the composition per serving. Tire dose can be expressed in grams / serving.

[0209] In various embodiments, the compositions disclosed herein can be administered orally in an amount ranging from about 1 g / serving to about 20 g / serving, from about 1 g / serving to about 15 g / serving, from about 1 g / serving to about 14 g / serving, from about 1 g / serving to about 13 g / serving, from about 1 g / serving to about 12 g / serving, from about 1 g / serving to about 11 g / serving, from about 1 g / serving to about 10 g / serving, from about 1 g / serving to about 9 g / serving. from about 1 g / serving to about 8 g / serving, from about Ig / serving to about 7 g / serving. from about 1 g / serving to about 6 g / serving, or from about 1 g / serving to about 5 g / serving.

[0210] In particular embodiments, the compositions disclosed herein can be administered orally in an amount of about 1 g / serving, about 2 g / serving, about 3 g / serving. about 4 g / serving, about 5 g / serving, about 6 g / serving. about 7 g / serving, about 8 g / serving, about 9 g / serving. about 10 g / serving. about 11 g / serving, about 12 g / serving, about 13 g / serving, about 14 g / serving, about 15 g / serving, about 16 g / serving, about 17 g / serving, about 18 g / serving, about 19 g / serving, or about 20 g / serving.

[0211] In various embodiments, the composition is a powdered fonnulation. In some embodiments, the composition is mixed with a food, food product, or beverage shortly before administration. For example, about 5 to about 20 g of a composition of the disclosure can be added to about 4 ounces to about 16 ounces of w ater or a water-based liquid, as defined in Section 3.4.

[0212] In various embodiments, the composition is incorporated into a food, food product, or beverage. For example, the solid dosage composition can be incorporated into w'ater, water-based liquids, milk, milk-based liquids, plant-based milks, coffee, tea, fruit juice, fruit drink, fruit blend, sports drink, smoothie, protein shake, energy drink, yogurt, yogurt blend, snack bar, energy bar, cookie, brownie, muffin, cracker, biscuit, and cereal or chocolate bar. The composition can be incorporated into a ready-to- eat or drink food, food product, or beverage or incorporated by the consumer into a food, food product, or beverage.

[0213] In various embodiments, the composition is suitable for oral administration once monthly, once weekly, or once daily (e.g., once momingly). Alternatively, the composition is subdivided and administered multiple times during a day.

[0214] 3.7 METHODS

[0215] The present disclosure provides a method of using the compositions disclosed in Sections 3.2 and 3.3. In various embodiments, the compositions can be used for improving gut health, for enhancing energy, for improving focus, for reducing cravings, for improving stress management, for improving health, for promoting healthy aging, for replenishing nutrients, for supporting immune health, for promoting skin health, for promoting hair and nail growth, and for enhancing recovery after physical activity.

[0216] Tire methods comprise administering an effective amount of a composition disclosed in Sections 3.2 and 3.3.

[0217] In various embodiments, the composition is administered once monthly, once weekly, or once daily (e.g., once momingly). Alternatively, the composition is subdivided and administered multiple times during a day. In some embodiments, the composition is administered once daily, consistently. It is believed that the benefits are cumulative and increase over time.

[0218] In embodiments in which the composition is effective for improving gut health, the composition is administered before, alongside, or after a meal. In some embodiments, the composition is administered alongside a meal, the composition is administered up to about 5 minutes, up to about 10 minutes, up to about 15 minutes, up to about 20 minutes, up to about 25 minutes, up to about 30 minutes, up to about 45 minutes, or up to about 60 minutes before the subject eats a meal, or the composition is administered up to about 5 minutes, up to about 10 minutes, up to about 15 minutes, up to about 20 minutes, up to about 25 minutes, up to about 30 minutes, up to about 45 minutes, or up to about 60 minutes after the subject eats a meal. In some embodiments, the composition is administered on an empty stomach. In some embodiments, administration of the composition improves gut health or the perception thereof by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, or at least about 50% in a subject. In embodiments in which the composition is effective for enhancing energy, the composition is administered before, alongside, or after a meal. In some embodiments, the composition is administered alongside a meal, the composition is administered up to about 5 minutes, up to about 10 minutes, up to about 15 minutes, up to about 20 minutes, up to about 25 minutes, up to about 30 minutes, up to about 45 minutes, or up to about 60 minutes before the subject eats a meal, or the composition is administered up to about 5 minutes, up to about 10 minutes, up to about 15 minutes, up to about 20 minutes, up to about 25 minutes, up to about 30 minutes, up to about 45 minutes, or up to about 60 minutes after the subject eats a meal. In some embodiments, the composition is administered on an empty stomach. In some embodiments, administration of the composition enhances energy or the perception thereof by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%. or at least about 50% in a subject.

[0219] In embodiments in which the composition is effective for improving focus, the composition is administered before, alongside, or after a meal. In some embodiments, the composition is administered alongside a meal, the composition is administered up to about 5 minutes, up to about 10 minutes, up to about 15 minutes, up to about 20 minutes, up to about 25 minutes, up to about 30 minutes, up to about 45 minutes, or up to about 60 minutes before the subject eats a meal, or the composition is administered up to about 5 minutes, up to about 10 minutes, up to about 15 minutes, up to about 20 minutes, up to about 25 minutes, up to about 30 minutes, up to about 45 minutes, or up to about 60 minutes after the subject eats a meal. In some embodiments, the composition is administered on an empty stomach. In some embodiments, administration of the composition improves focus or the perception thereof by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%. at least about 45%. or at least about 50% in a subject.

[0220] In embodiments in which the composition is effective for reducing cravings, the composition is administered before, alongside, or after a meal. In some embodiments, the composition is administered alongside a meal, the composition is administered up to about 5 minutes, up to about 10 minutes, up to about 15 minutes, up to about 20 minutes, up to about 25 minutes, up to about 30 minutes, up to about 45 minutes, or up to about 60 minutes before the subject eats a meal, or the composition is administered up to about 5 minutes, up to about 10 minutes, up to about 15 minutes, up to about 20 minutes, up to about 25 minutes, up to about 30 minutes, up to about 45 minutes, or up to about 60 minutes after the subject eats a meal. In some embodiments, the composition is administered on an empty stomach. In some embodiments, administration of the composition reduces cravings or the perception thereof by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, or at least about 50% in a subject. In embodiments in which the composition is effective for improving stress management, the composition is administered before, alongside, or after a meal. In some embodiments, the composition is administered alongside a meal, the composition is administered up to about 5 minutes, up to about 10 minutes, up to about 15 minutes, up to about 20 minutes, up to about 25 minutes, up to about 30 minutes, up to about 45 minutes, or up to about 60 minutes before the subject eats a meal, or the composition is administered up to about 5 minutes, up to about 10 minutes, up to about 15 minutes, up to about 20 minutes, up to about 25 minutes, up to about 30 minutes, up to about 45 minutes, or up to about 60 minutes after the subject eats a meal. In some embodiments, the composition is administered on an empty stomach. In some embodiments, administration of the composition improves stress management or the perception thereof by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%. or at least about 50% in a subject.

[0221] In embodiments in which the composition is effective for improving health, the composition is administered before, alongside, or after a meal. In some embodiments, the composition is administered alongside a meal, the composition is administered up to about 5 minutes, up to about 10 minutes, up to about 15 minutes, up to about 20 minutes, up to about 25 minutes, up to about 30 minutes, up to about 45 minutes, or up to about 60 minutes before the subject eats a meal, or the composition is administered up to about 5 minutes, up to about 10 minutes, up to about 15 minutes, up to about 20 minutes, up to about 25 minutes, up to about 30 minutes, up to about 45 minutes, or up to about 60 minutes after the subject eats a meal. In some embodiments, the composition is administered on an empty stomach. In some embodiments, administration of the composition improves health or the perception thereof by at least about 5%. at least about 10%. at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, or at least about 50% in a subject.

[0222] In embodiments in which the composition is effective for promoting healthy aging, the composition is administered before, alongside, or after a meal. In some embodiments, the composition is administered alongside a meal, the composition is administered up to about 5 minutes, up to about 10 minutes, up to about 15 minutes, up to about 20 minutes, up to about 25 minutes, up to about 30 minutes, up to about 45 minutes, or up to about 60 minutes before the subject eats a meal, or the composition is administered up to about 5 minutes, up to about 10 minutes, up to about 15 minutes, up to about 20 minutes, up to about 25 minutes, up to about 30 minutes, up to about 45 minutes, or up to about 60 minutes after the subject eats a meal. In some embodiments, the composition is administered on an empty stomach. In some embodiments, administration of the composition promotes healthy aging or the perception thereof by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, or at least about 50% in a subject.

[0223] In embodiments in which the composition is effective for replenishing nutrients, the composition is administered before, alongside, or after a meal. In some embodiments, the composition is administered alongside a meal, the composition is administered up to about 5 minutes, up to about 10 minutes, up to about 15 minutes, up to about 20 minutes, up to about 25 minutes, up to about 30 minutes, up to about 45 minutes, or up to about 60 minutes before the subject eats a meal, or the composition is administered up to about 5 minutes, up to about 10 minutes, up to about 15 minutes, up to about 20 minutes, up to about 25 minutes, up to about 30 minutes, up to about 45 minutes, or up to about 60 minutes after the subject eats a meal. In some embodiments, the composition is administered on an empty stomach. In some embodiments, administration of the composition replenishes nutrients or the perception thereof by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, or at least about 50% in a subject.

[0224] In embodiments in which the composition is effective for supporting immune health, the composition is administered before, alongside, or after a meal. In some embodiments, the composition is administered alongside a meal, the composition is administered up to about 5 minutes, up to about 10 minutes, up to about 15 minutes, up to about 20 minutes, up to about 25 minutes, up to about 30 minutes, up to about 45 minutes, or up to about 60 minutes before the subject eats a meal, or the composition is administered up to about 5 minutes, up to about 10 minutes, up to about 15 minutes, up to about 20 minutes, up to about 25 minutes, up to about 30 minutes, up to about 45 minutes, or up to about 60 minutes after the subject eats a meal. In some embodiments, the composition is administered on an empty stomach. In some embodiments, administration of the composition supports immune health or the perception thereof by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%. or at least about 50% in a subject.

[0225] In embodiments in which the composition is effective for promoting hair and nail growth, the composition is administered before, alongside, or after a meal. In some embodiments, the composition is administered alongside a meal, the composition is administered up to about 5 minutes, up to about 10 minutes, up to about 15 minutes, up to about 20 minutes, up to about 25 minutes, up to about 30 minutes, up to about 45 minutes, or up to about 60 minutes before the subject eats a meal, or the composition is administered up to about 5 minutes, up to about 10 minutes, up to about 15 minutes, up to about 20 minutes, up to about 25 minutes, up to about 30 minutes, up to about 45 minutes, or up to about 60 minutes after the subject eats a meal. In some embodiments, the composition is administered on an empty stomach. In some embodiments, administration of the composition promoting hair and nail growth or the perception thereof by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, or at least about 50% in a subject.

[0226] In embodiments in which the composition is effective for enhancing recovery after a physical activity, the composition is administered while the subject performs one or more types of exercise, before the subject performs one or more types of exercise, or after the subject performs one or more types of exercise. In some embodiments, the composition is administered while the subject performs one or more types of exercise, the composition is administered up to about 5 minutes, up to about 10 minutes, up to about 15 minutes, up to about 20 minutes, up to about 25 minutes, up to about 30 minutes, up to about 45 minutes, or up to about 60 minutes before the subject performs one or more exercises, or the composition is administered up to about 5 minutes, up to about 10 minutes, up to about 15 minutes, up to about 20 minutes, up to about 25 minutes, up to about 30 minutes, up to about 45 minutes, or up to about 60 minutes after the subject performs one or more exercises. In some embodiments, the composition is administered on an empty stomach. In some embodiments, administration of the composition enhances recovery, or the perception thereof, by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, or at least about 50% in a subject.

[0227] 3.8 KITS

[0228] In various embodiments, the present disclosure provides kits comprising a composition as disclosed herein. In other embodiments, the present disclosure provides packaging comprising a composition as disclosed herein. The packaging can be dose packets, travel packs, pouches, sachets, bottles, stick-packs, or the like. The packaging may contain a quantity of composition suitable for at least one dose, at least two doses, at least three doses, at least four doses, at least 5 doses, at least 6 doses, at least 7 doses, at least 8 doses, at least 9 doses, at least 10 doses, at least 15 doses, at least 20 doses, at least 25 doses, or at least 30 doses.

[0229] In one embodiment, the kit further comprises instructions for using a composition as disclosed herein. The instructions can be in any appropriate form, such as written or electronic form. In another embodiment, the instructions can be written instructions. In another embodiment, the instructions are contained in an electronic storage medium (e.g., magnetic diskette or optical disk). In one embodiment, the instructions include information as to the composition and the manner of administering the composition to a subject. In another embodiment, the instructions relate to a method of use disclosed in Section 3.7.

[0230] A dose packet, travel pack, pouch, sachet, bottle, stick-pack and the like may be opened, and its contents mixed with food, a food product, or a beverage to provide the daily dose of a composition of the disclosure. In some embodiments, the dose packet may be mixed with about !4 cup a beverage (e.g., water), !4 cup beverage, ! cup beverage, 50 mL beverage, or 25 mL beverage. In at least one example, the dose packet is mixed with !4 cup beverage (e.g., water) (about 80 mL) to form an oral suspension for administration to the subject. In at least one additional example, the dose packet, travel pack, pouch, sachet, bottle, stick-pack, or the like is mixed with about 50 mL in a mixing cup to form an oral suspension for administration to the subject. The mixing cup may be additionally filled with about 25 mL after administration of the oral suspension to suspend any remaining composition in the mixing cup to fomr a second oral suspension for administration to the subject. In other examples, only one suspension may be needed to administer the full dosage to the subject. Suspensions may be consumed within about 5 minutes, about 10 minutes, about 20 minutes, about 30 minutes, about 40 minutes, about 50 minutes, about 60 minutes, or longer.

[0231] In some embodiments, a kit may comprise one or more components to assist in the administration of a composition disclosed herein (e.g., measuring spoons or cups, spoons, and straws). In other embodiments, a kit may comprise a composition disclosed herein and a food product wherein the composition may be incorporated into the food product. In one aspect, a food product for use herein may be a drink (e.g., water, water-based liquids, milk, milk-based liquids, plant-based milks, coffee, tea, fruit juice, fruit drink, fruit blend, sports drink, smoothie, protein shake, energy drink). In another aspect, a food product for use herein may be a solid food product (e.g., yogurt, yogurt blend, snack bar, energy bar, cookie, brownie, muffin, cracker, biscuit, and cereal or chocolate bar).

[0232] 4. EXAMPLES

[0233] The following examples are presented for illustrative purposes and should not serve to limit the scope of the disclosed subject matter.

[0234] Unless otherwise specified, the Test Formulation of the disclosure was prepared by mixing about 13 g of a composition of the disclosure with about 10 ounces of water. The Comparative Formulation (AG1 ® (iteration 52), commercially available from AG1) was similarly prepared. Tire Probiotic Comparator was a 15 Billion CFU probiotic, which is commercially available as a capsule. 4.1 - Example 1 - In Vitro Probiotic and Prebiotic Efficacy of Compositions in Short Term Colonic Simulations using the Test Formulation and the Comparative Formulation

[0235] An in vitro experiment was conducted using tire Simulator of the Human Intestinal Microbial Ecocystem (SHIME®) model. This particular model is a dynamic simulation of the human gastrointestinal tract replicating physiological conditions of the stomach, small intestine, and proximal colon which is frequently used to understand the digestive and fermentative capacity of test compounds, including dietary supplements.

[0236] 4.1.1. Materials and Methods

[0237] A Test Formulation (6.5 g / rcactor) and a Comparative Formulation (6 g / rcactor) were separately predigested assuming fasted conditions in a gastric simulation phase using enzymes (1000 U / mL pepsin, 0.02 mM phosphatidylcholine) and salts (50 mM sodium chloride, 7 mM potassium chloride) physiologically relevant conditions (37 °C for 45 minutes and at a pH of 2 with constant stirring). The small intestine simulation was used to remove the digestible fraction via dialysis. The gastric simulation was slowly neutralized over 27 minutes and then held at a pH of 7 for 3 hours at 37 °C. Pancreatic enzymes (1.12 TAME U / mL pancreatin, 3.1 TAME U / mL trypsin, 0.76 BTEE U / mL chymotrypsin) and bile salts (3.33 mM bovine bile extract). Dialysis was conducted using a cellulose membrane with a pore size cut off of 15 kDa. with the dialysis solution being refreshed every hour.

[0238] Tire remaining fraction was added to a short-term colonic simulation to replicate proximal colonic conditions. Fecal inoculum was derived from cryopreserved fecal slurries and collected from 8 healthy adult donors (BMI 18.5-24.9, no recent antibiotic use. aged 20-45 years). Each colonic bioreactor was prepared using 7 mL of fecal inoculum, 10 mL of the nondigested fraction, and 53 mL of a colonic basal medium (containing peptone, yeast extract, and L-cysteine). Nitrogen gas was flushed in to establish an anaerobic environment, and each bioreactor was shaken constantly at 90 rpm at 37 °C for 48 hours. Tire study was conducted in 3 technical replicates for 2 arms. A total of 48 simulations were run.

[0239] In the short-term colonic simulation, a representative dose of test samples were incubated under simulated conditions for the proximal large intestine (temperature and pH). In some experiments, the colon microbiology were absent (i.e., sterile colon) or inoculated with a fecal sample (i.e., colonized colon). In a colonized colon, a fresh fecal sample from a single donor was used so as to maximize microbial diversity and realism. Aliquots of test solution are collected and assessed for microbial community activity (5.1.2.) and gut permeability and immunomodulator effects - THP (5.1.3.) after a period of time, e.g., Oh (control group), about 6h, about 24h, and about 48h.

[0240] 4.1.2. Microbial Community Activity

[0241] For analysis of the microbial community activity, aliquots of test solution were collected and assessed after a period of time, e.g., about Oh, about 6h, about 24h, and about 48h of colonic digestion.

[0242] Short Chain Fatty ’ Acid Analysis (SCFA): Test solutions were assessed for microbial carbohydrate metabolism (acetate, propionate and butyrate) or protein metabolism (branched short chain fatty acid: isobutyratc, isovalcratc and isocaproatc) and compared to typical fermentation patterns for normal GI microbiota. For the SCFA assessment, each fatty acid was measured at about Oh (controls only), Ih, 24h, and 48h.

[0243] Lactate: Test solutions were assessed for lactate. The intestine harbors both lactate -producing and lactate-utilizing bacteria. Lactate is produced by lactic acid bacteria and decreases the pH of tire environment, acting also as an antimicrobial agent. It can also be rapidly converted to acetate, butyrate, and propionate by other microorganisms. For the lactate assessment, lactate is measured using the Enzytec™ kit at about Oh (controls only), Ih, 24h, and 48. pH or acid / base consumption: Test solutions were assessed for pH or acid / base consumption. Tire degree of acidification is a measure of the intensity of bacterial metabolism, with the various time points giving insight into the speed of fermentation.

[0244] Ammonium analysis: Test solutions were assessed for ammonium. Ammonium is a product of proteolytic degradation, which results in the production of potentially toxic or carcinogenic compounds, such as i-cresol and p-phenol. For the ammonium assessment, ammonium is measured colorimetrically using the indophenol method at about Oh (controls only), about 24h, and about 48h.

[0245] Gas analysis: Test solutions were analyzed for gas production. Tire kinetics of the total gas production were analyzed through the experiment. The excessive production of gas is considered as a potentially negative side-effect of increased saccharolytic activity of the intestinal community upon administration of a Test Formulation. As different bacterial groups produce different amounts of gasses, the substrate specific stimulation of certain microbial groups will allow for more or less gas production. Gas analysis is performed at about 6h, about 24 h, and about 48 h. 4.1.3. Gut Permeability and Immunomodulator Effects - THP

[0246] Test solutions were analyzed for gut permeability and immunomodulatory effects at about 48h.

[0247] Co-culture model of enterocytes and macrophages'. The Caco-2 human colon adenocarcinoma epithelial cell line is a commonly used human intestinal epithelial-like cell line, widely used as an in vitro model of the small intestinal mucosa to predict the absorption of orally administered drugs. Caco-2 cells are seeded onto a semi-permeable membrane insert where they grow into a confluent monolayer in 14 days under standard cell culture conditions (37 °C, 5% CO2. humidified atmosphere) in Dulbccco’s Modified Eagle Medium (DMEM) supplemented with glucose, glutamine, HEPES buffer, and 20% (v / v) heat-inactivated fetal bovine serum (FBS). This provides a physical and biochemical barrier to the passage of ions and small molecules. At this stage, cells are differentiated and polarized in such a way that, both morphologically and functionally, they resemble the enterocyte lining in the human small intestine. When these calls are co-cultured with PMA-activated THP-1 macrophages (i.e., a human monocytic cell line), THP-1 induced inflammation occurs and causes the disruption of the Caco-2 monolayer. Upon LPS stimulation, the THP1 cells further produce cytokines. This in vitro leaky gut model is representative of the processes that occur during low grade inflammation in the gut.

[0248] To prepare a leaky gut simulation, Caco-2 cells were cultured in Transwell® inserts placed on top of THP-1 cells. Once THP-1 cells became activated macrophages, they produced inflammatory cytokines, which were secreted into the basolateral compartment and disrupted the Caco-2 monolayer cultured in the apical side of the Transwell®. Test formulations - either A Test Formulation, either pure or as a complex sample from some stage of SHIME digestion - was added to the leaky gut simulation on the apical side of the co-cultures.

[0249] Gut permeability: THP-1 -induced damage on the Caco-2 cell monolayer was assessed by measuring its transepithelial electrical resistance (TEER). A decrease in TEER is an indication of monolayer disruption.

[0250] Immune parameters: Using co-cultures of Caco-2 / THPl XBlue, the production of cytokines in the basolateral compartment was measured (human IL- 113, TL-6, IL-8, IL-10, TNF-a, CXCL10 and MCP- 1 by Luminex multiplex - Affymetrix-eBioscience) together with NF-KB activity.

[0251] 4.1.4 - Results

[0252] Comparative Formulation: The metabolic activity analysis revealed that administration of the Comparative Formulation stimulated the gut microbial communities across timepoints and donors, with some unique kinetic and compositional profiles compared to other formulations. Specifically, the Comparative Formulation led to a significant increase in total gas production over the 0-lh, 0-24h, and 0-48h periods, though the total gas produced remained below 40 kPa, suggesting moderated but sustained fermentative activity. This temporal pattern indicates early and sustained microbial engagement with the Comparative Formulation.

[0253] In terms of environmental pH, no substantial net change was observed across the fermentation period. Notably, the Comparative Formulation generated a slightly basic environment immediately upon administration, likely due to the intrinsic alkalinity of certain fonnulation ingredients. Overtime (0-24h and 0-48h), the Comparative Formulation remained marginally more basic than the control, though the net acidification remained minor (below 0.2 pH units), indicating that the Comparative Formulation does not dramatically alter colonic pH homeostasis.

[0254] The analysis of microbial metabolites demonstrated a significant enhancement in the production of key short-chain fatty acids (SCFAs) at 0-24h and 0-48h. Specifically, total SCFAs increased by 44.1%, acetate by 49%, and propionate by 70.8% relative to the control. However, the increase in butyrate was statistically insignificant, with a modest numerical rise of 16.4%. These results suggest that the Comparative Formulation supports saccharolytic fermentation processes, particularly those leading to acetate and propionate production, without strongly promoting butyrate synthesis.

[0255] Regarding protein fermentation markers, the Comparative Formulation induced a significant increase in ammonium production at 0-48h, but not at 0-24h, suggesting the onset of proteolytic fermentation occurs at a delayed rate. Despite this, there were no significant increases in branched SCFAs (bSCFAs) at any timepoint, implying that while protein fermentation occurred, it predominantly yielded other nitrogenous products aside from bSCFAs.

[0256] Evaluation of host-microbiome interactions using the in vitro Caco-2 / THP-l co-culture model demonstrated that the Comparative Formulation conferred a protective effect on epithelial barrier integrity, as evidenced by a significant preservation of TEER (transepithelial electrical resistance) values compared to the control, which exhibited substantial barrier disruption. This indicates a potential for the Comparative Formulation to maintain tight junction integrity under inflammatory challenge.

[0257] However, no significant immunomodulatory’ effects were observed in cytokine or chcmokinc production, the Comparative Formulation did not alter the expression of NF-KB activity, nor did it significantly affect the levels of IL-6, IL-10. IL-ip, TNF-a, CXCL10, MCP-1, or IL-8. This suggests that the Comparative Formulation maintains immune homeostasis without provoking either pro- or antiinflammatory responses under the conditions tested.

[0258] Test Formulation: The metabolic activity analysis indicated that administration of the Test Formulation had a clear stimulating effect on the metabolic activity of the gut microbial communities of the different donors. More specifically, administration of pre-digested Test Formulation resulted in a significantly reduced environmental pH (acidification) and a significantly enhanced production of gas, acetate, propionate, butyrate, and (b)SCFA. This was likely the result of the higher nutrient load being present in the simulated colonic environment upon administration of the formulation. In addition, the surviving probiotic bacteria likely augment this enhanced overall metabolic activity as tire supplemented probiotic species should be able to fonn SCFAs as a result of their metabolic activity. Administration of the Probiotic Comparator only had a mild effect on the different activity parameters, indicating that even though the probiotic strains directly or indirectly affected the gut microbiome, they were not able to significantly affect overall microbial functionality.

[0259] Regarding the host-microbiome interactions, colonic fermentation of the Test Fonuulation significantly protected against inflammation-induced barrier disruption across donors in the in vitro Caco- 2 / THP1 co-culture model. Furthermore, the Test Formulation demonstrated anti-inflammatory properties by significantly increasing tire secretion of anti-inflammatory cytokines IL-10 and IL-6. However, the Test Fonnulation also showed pro-inflammatory properties by enhancing the levels of the pro- inflammatory cytokines IL-1 p and TNF-a, as well as the chemokine IL-8. In contrast, colonic fermentation of the Probiotic Comparator did not protect against inflammation-induced barrier disruption and the immuno-modulatory effects were mild and donor-dependent.

[0260] Comparative Analysis of Test Formulation and Comparative Formulation: A comparative analysis of the Test Formulation and Comparative Formulation in the SHIME model revealed that the Test Formulation demonstrated superior fermentative and immunomodulatory properties relative to the Comparative Formulation. Both formulations increased gas production across all time points, indicating active microbial fermentation; however, the Test Formulation produced total gas volumes exceeding 40 kPa, whereas the Comparative Formulation remained below this threshold, suggesting a more robust fermentative response in the Test Formulation. Similarly, acidification of the simulated colonic environment was more pronounced in the Test Formulation, with a net pH reduction of up to 0.3 points compared to the 0.2-point reduction observed with the Comparative Formulation. While both formulations led to modest lactate accumulation, likely due to rapid downstream conversion into other metabolites, the Test Formulation consistently outperformed the Comparative Formulation in the production of short-chain fatty acids (SCFAs). Total SCFAs increased by 57. 1% with the Test Formulation versus 44. 1% with the Comparative Formulation; propionate increased by 83.9% versus 70.8%; and butyrate by 33.1% compared to 16.4%. respectively. Acetate production was comparable between the two versions. Distinct differences in protein fermentation markers were observed, with the Comparative Formulation significantly increasing ammonium production, indicative of proteolytic activity, while the Test Formulation showed significant increases in branched-chain SCFAs (bSCFAs), suggesting alternate proteolytic pathways.

[0261] Both versions preserved epithelial barrier integrity as demonstrated by stable transepithelial electrical resistance (TEER) values. However, the Test Formulation exhibited a more pronounced immunomodulatory effect, significantly increasing both anti-inflammatory cytokines (IL-6, IL- 10) and pro-inflammatory markers (IL-ip, TNF-a, IL-8), indicative of a balanced immune response following LPS-induced inflammatory challenge. In contrast, the Comparative Formulation did not significantly modulate cytokine or chemokine expression. Overall, the Test Formulation provided a more dynamic and biologically active profile in terms of fermentation efficiency, metabolite production, and host-relevant immunological outcomes.

[0262] 4.2 - Example 2 - In Vivo Pharmacokinetic Studies of the Test Formulation

[0263] This study was designed to assess how the Test Formulation affects the absorption and metabolism of key vitamins, minerals, and phytonutrients in healthy adults. Using a randomized, doubleblind, placebo-controlled crossover design, the primary goal was to compare postprandial blood concentrations of nutrients (e.g.. vitamin C, B-complex vitamins, zinc, and polyphenols) following treatment with the Test Formulation and a Placebo Formulation (consisting of approximately 13 g of maltodextrin with flavoring). A secondary aim was to evaluate short-term subjective responses, such as bloating, energy, and mood.

[0264] 4.2.1 - Test Formulations and Protocol

[0265] Participants were randomly assigned to receive each of the following test products in a counterbalanced fashion on separate visits with at least one week between visits: (1) Test Fonnulation, and (2) a Placebo Formulation. Treatments were provided as powders in pre-sized individual sachets, each delivering 13 grams of material to be mixed with 10 oz of water. Participants consumed their assigned supplement under the supervision of the research staff. Participants replicated their 24-hour pre-test diet before each visit, avoided caffeine and exercise the day before, and completed an overnight fast. Blood work was analyzed by a laboratory to evaluate blood concentrations of folate, calcium, zinc, vitamin C, biotin, nicotinamide, riboflavin, thiamin, pyridoxine and hesperiden. Dietary records were analyzed using the Nutritionix platfonn.

[0266] Sixteen healthy adults aged 18-45 completed three visits: an initial screening followed by two testing days (each separated by approximately a week). On day 1, the study subjects provided an initial baseline blood sample. The study subjects then consumed 1 dose of the Test Formulation or Placebo Formulation with 10 oz. of water. Blood samples were drawn at predetermined intervals over an 8h period in a fasted state. About day 8 or later, the study subjects returned and completed the opposite condition (a Test Formulation or Placebo Formulation). Serial blood draws were taken over an 8-hour period to capture nutrient kinetics (AUC, Cmax, Tmax, and half-life). Participants also rated their gastrointestinal comfort and overall well-being via visual analog scales during tire first 2 hours after ingestion.

[0267] 4.2.2 - Blood Collection Procedures

[0268] Blood draws were conducted during each laboratory' visit. At the screening visit, a single blood draw was performed, with a total blood volume of approximately 12 mL. During visits 2 and 3, serial blood draws were perfonned prior to and at 30, 60, 90, 120, 180, 240, 360, and 480 minutes following ingestion of the investigational product. An intravenous catheter (flexible tubing to facilitate blood sampling) was inserted into a vein in the upper extremity to enable repeated sampling.

[0269] 4.2.3 - Results - Nutrient Gaps Results

[0270] All sixteen subjects (31 ± 9 years and 50% F) completed their respective dietary' recalls and were included in the nutrient gap analysis. After the interventional nutrient values were added to the recalls, the Test Formulation and Placebo Formulation groups met 14.9 ± 1.4 and 10.7 ± 4.0 out of 16 nutrient EARs, respectively. Tire mean difference for the number of nutrient requirements met between conditions was

[0271] 4.3 ± 3.2 (P < 0.0001). Vitamins C, A. and E were the most common nutrient requirements met in the Test Formulation group compared to the Placebo Formulation group.

[0272] Compared to the Placebo Formulation, consumption of the Test Formulation resulted in a significantly higher AUCO-t (p < 0.05) for folate, calcium, zinc, vitamin C, biotin, nicotinamide, riboflavin, and thiamin over the course of 8 hours. A trend (p = 0.075) for higher pyridoxine AUCO-t was found in the Test Formulation treatment group compared to placebo and pyridoxine concentrations were significantly elevated (p <0.05) within 30 minutes following Test Formulation vs. Placebo Formulation. Additionally, hesperiden concentrations were significantly elevated (p > 0.05) following the Test Formulation consumption compared to the Placebo Formulation at 180min.

[0273] The Test Formulation closed nutrient gaps by fulfilling significantly more nutrient requirements (p < 0.05) compared to the Placebo Formulation. The Test Formulation’s supplementation fulfilled 21.9% more nutrient requirements than the placebo treatment. No adverse events reported or observed over 8- hours following supplementation with the Test Formulation. No differences in gas, bloating, heart rate, or blood pressure following supplementation with the Test Formulation.

[0274] 4.2.3 - Conclusions

[0275] These data demonstrate that all vitamins and minerals that were measured in the Test Formulation were absorbed and entered circulation following consumption. The results of this study validate the ability of the Test Formulation to effectively increase circulating nutrient levels, indicating good bioavailability, while significantly improving nutrient adequacy in healthy adult males and females.

[0276] 4.3 - Example 3 - In Vivo Studies on the Nutritional Status, Biomarkers of Health, and Clinical Safety of the Test Formulation

[0277] 4.3.1 - Objective and methods

[0278] A 12-week study was conducted to assess the effects of the Test Formulation on nutritional status and cardiometabolic risk markers in an average US population. In this study, 120 apparently healthy adults (18-59 years) were enrolled in a randomized, double blind, placebo-controlled study.

[0279] Test subjects were selected to match with the normal US population’s intake of fruits and vegetables by screening The Diet History Questionnaire III (DHQIII). a freely available and validated food frequency questionnaire (FFQ) developed by the National Cancer Institute (NCI) Division of Cancer Control and Population Sciences.

[0280] Test subjects supplemented with the Test Formulation (n=60) or PL (n=60) for 12 weeks and provided a blood sample pre and post intervention to assess markers of nutrient status (homocysteine, vitamin B12, serum folate, RBC folate, zinc, vitamin C) and overall health (homocysteine). Additionally, test subjects completed validated questionnaires to assess digestive health, fatigue, and quality of life and provide a detailed dietary record. Test subjects provided a fecal sample for microbiome analysis and to provide SCFA and / or metagenomic insight from a large sample size. 4.3.2 - Blood Nutrient Status, Clinical Safety Markers, & Adverse events

[0281] A fasted, resting blood draw was completed before (PRE) and following (POST) 12-weeks of daily supplementation for assessment of nutrient status markers at a local hematology laboratory. Markers of nutrient status (homocysteine, vitamin B 12, serum folate. RBC folate, zinc, vitamin C) and overall health (homocysteine) were assessed and utilized for analysis. Fasting blood samples were additionally utilized to assess markers of renal, hepatic, metabolic and overall health [Complete Blood Count (CBC), Comprehensive Metabolic Panel (CMP), lipid panel, clinical hematological markers] . Self-reported adverse events were monitored throughout the study duration to assess the incidence rates of other potential side effects.

[0282] 4.3.3 - Nutrient Gaps

[0283] Participants were asked to maintain their normal diet and the ASA24® was used to assess dietary intake at baseline and endpoint (nutrient values from AG1 or placebo added). Nutrient gaps were defined as the difference between an individual's reported dietary intake and established dietary targets [the Estimated Average Requirements (EARs) for specific nutrients] . Sixteen micronutrients were included in the assessment based on the following criteria: the micronutrients were present in the Test Formulation, could be measured by ASA24®, and had an EAR. A combined nutrient gap score was calculated with the summation of nutrient intakes that met the EAR (each nutrient EAR met = 1 for a maximum score of 16).

[0284] 4.3.4 - Subjective Questionnaires

[0285] The Mean Fatigue Index (MFI) is a validated self-report questionnaire designed to assess multiple dimensions of fatigue including general, physical, and mental fatigue, reduced motivation, and reduced activity using. The World Health Organization - Five Well-Being Index (WHO-5) is a validated, short self-report questionnaire used to measure current mental well-being, focusing on positive mood, vitality, and general interest. Data from validated questionnaires were collected using textual 3-, 4-, 5-, 6-, or 7- point Likert scales for each question. The textual Likert data was transformed into numerical values as per the validated scoring system. The adapted MFI questionnaire was graded out of a total of 95. The adapted WHO-5 questionnaire was graded out of a total raw score of 20, and the final score was multiplied by 5 to give a percentage.

[0286] The Gastrointestinal Symptom Rating Scale (GSRS) is a validated questionnaire used to assess the severity and frequency of common gastrointestinal symptoms such as bloating, abdominal pain, reflux, and indigestion. The questionnaire is organized into two sections, both including four to seven questions. Section 1 addresses upper abdominal issues (reflux, heartbum, bloating, cramps, vomiting, nausea) and Section 2 addresses lower abdominal issues (intestinal cramps, flatulence, urge to defecate, left abdominal pain, right abdominal pain, loose stool, diarrhea). Each participant completed the 13 items on a 10-point scale ranging from 0 (no problem at all) to 9 (the worst it has ever been). Adverse events were monitored throughout the study period.

[0287] 4.3.5 - Results - Summary

[0288] Primary outcomes included nutrient status of key micronutrients, micronutrient gaps, microbiome effects, and safety following supplementation with the Test Formulation.

[0289] • Tire Test Formulation significantly improved nutrient status markers in adults eating a normal US diet (Vitamin C. Serum Folate, Red Blood Cell Folate, Folate Hemolysate, and Homocysteine).

[0290] • Tire Test Formulation closed nutrient gaps by fulfilling significantly more nutrient requirements in adults whose diet mirrors the average US adult.

[0291] • The Test Formulation enriched healthy probiotic bacteria species in the gut after 12 weeks of supplementation [10 taxa (or 6 beneficial species) were significantly increased following Test Formulation consumption],

[0292] • No negative changes in clinical blood safety markers following 12 weeks of supplementation with the Test Fonnulation.

[0293] • No adverse events following supplementation with the Test Formulation.

[0294] • No negative effects on liver enzymes, blood values, or GI symptoms following supplementation with the Test Formulation.

[0295] 4.3.5.1 - Results: Nutrient Gaps

[0296] Of the 120 participants, 98 (41 ± 10 years and 74.5% F) completed baseline and endpoint recalls and were included in the nutrient gap analysis. At baseline, the Test Formulation and placebo groups met 11.2 ± 3.5 and 10.8 ± 4.3 out of 16 nutrient EARs, respectively with no significant difference between groups (p > 0.05). Following the intervention, the Test Formulation group significantly increased the total number of EARs met compared to the Placebo Formulation group [3.8 (95% CI: 2.5, 5.2): p < 0.0001], Within the Test Formulation group, 3.8 (95% CI: 2.7, 5.0) nutrient gaps were closed compared to 0.4 (95% CI: -0.8, 1.6) in the placebo group. Zinc, vitamins A, C, and E were the most common nutrient gaps filled by the Test Formulation intervention.

[0297] 4.3.S.2 - Results: Nutrient Status

[0298] Of the 120 enrolled participants, 105 adults completed PRE and POST blood testing (41.4 ± 10 y; n = 77 female) of circulating vitamin C, serum folate, red blood cell folate, homocysteine, and zinc concentrations. Two-way (treatment group x time) ANOVAs revealed significant (p < 0.05) time bytreatment group effects in which there were significant increases in the Test Formulation group compared to the placebo group for vitamin C (33% increase; p < 0.001), serum folate (26% increase: p < 0.001), red blood cell folate (6% increase; p < 0.001), folate hemolysate (9.9% increase; p < 0.05), and a significant decrease in homocysteine (10% decrease, p = 0.014) following the 12 week intervention. Neither the Test Formulation group nor the placebo group demonstrated improvements in serum zinc or vitamin B12 concentrations between PRE and POST testing (p > 0.05). Additionally. ASA24® dietary analysis confirmed no differences p > 0.05) in dietary intake of vitamin C. folate, or zinc between groups over the 12-week intervention apart from the nutrient content of the Test Formulation supplement in the Test Formulation group.

[0299] 4.3.S.3 - Results: Microbiome

[0300] Of the 120 participants, 99 provided baseline and endpoint stool samples. No significant differences were detected in the number of observed species or Pielou’s Evenness between the two treatment groups. There were no significant differences in overall community composition as indicated by permanova analysis (p > 0.05). Despite this, there was clear clustering between the treatment groups at each time point using PLS-DA ordination. LEfSe was used to identify any biomarkers that could explain the clustering observed in the ordination. Supplementation with the Test Formulation lead to significant (p < 0.0001) enrichment of 10 taxa including Bifidobacterium animalis. Lacticaseibacillus rhamnosus. Lactobacillus acidophilus. Lacticaseibacillus easel. and Lactiplantibacillus plantarum. Further, the enrichment of various taxa caused several gene pathways to have greater representation within the microbiome implying potential metabolic benefits that could be conferred to the host.

[0301] 4.3.5.4 - Results: Questionnaire

[0302] There were no significant differences (p <0.05) between the Test Formulation and Placebo Formulation groups for the MFI, WHO-5, or the GSRS following the 12-week intervention period. 4.3.5.5 - Results: Clinical Blood Safety Markers & Adverse Events

[0303] Of the participants randomized, 105 adults completed PRE and POST blood testing (41 ± 10 years; n = 28 males). There were no significant differences in the participants' dietary intake outside of the assigned treatments. Two-way (treatment group x time) ANCOVAs revealed no significant (p > 0.05) effects on any clinical blood safety markers with no adverse events reported for either treatment.

[0304] 4.3.6 - Conclusions

[0305] Test Formulation consumption significantly increased blood vitamin C, serum folate, red blood cell folate, folate hemolysate, and decreased homocysteine in healthy adults. Additionally, Test Formulation consumption significantly improved nutrient adequacy by reducing nutrient gaps. Test Formulation supplementation significantly improved the community structure and function of the gut microbiome. Test Formulation consumption over the 12 weeks did not adversely affect renal, hepatic, or other safety markers in healthy adults. Additionally, no adverse events were reported.

[0306] 4.4 - Example 4 - In Vivo Studies on Gut Microbiome Composition, Gastrointestinal Tolerability, and Clinical Safety of the Comparative Formulation

[0307] 4.4.1 - Objective and Study Design

[0308] This randomized, double-blind, placebo-controlled, parallel-arm clinical trial was conducted to assess the effects of the Comparative Formulation on the gut microbiome, digestive health, and clinical safety markers in healthy adult men and women. The primary objectives were to evaluate structural and functional changes in the gut microbiome following supplementation with the Comparative Formulation, while secondary objectives included assessments of gastrointestinal symptom burden, subjective digestive quality of life, and adverse clinical outcomes.

[0309] Thirty adults (15 males and 15 females; aged 39 ± 8.6 years; BMI: 25.2 ± 2.9 kg / m2) were randomized to receive either Comparative Formulation or a matched placebo (12 g maltodextrin with flavoring) once daily for four weeks. Participants were screened for inclusion based on standard clinical criteria and underwent assessments at three time points: screening (Visit 1), baseline (Visit 2). and postintervention (Visit 3, following four weeks of supplementation). The study protocol was approved by the WCG Institutional Review Board and registered at ClinicalTrials.gov (NCT06181214).

[0310] Participants provided stool samples at baseline and post-intervention using DNA / RNA-stabilized home collection kits for microbiome sequencing. Fecal genomic DNA was isolated and sequenced using Illumina NovaSeq platforms. Functional pathways were inferred from MetaCyc annotations and analyzed alongside taxonomic abundances. Clinical safety data, including CBC, CMP, lipid panel, and vital signs, were collected pre- and post-intervention. Subjective assessments included visual analog scales (VAS) for stool consistency and bowel frequency, the validated 9-item Digestion-Associated Quality of Life Questionnaire (DQLQ), the Bristol Stool Form Scale, and the Framingham Physical Activity Questionnaire. Compliance was verified through daily logs and returned sachets, with >96% adherence observed.

[0311] 4.4.2 - Statistical Analysis

[0312] Microbiome community structure (alpha and beta diversity) was analyzed using two-way ANOVA (Shannon and Chaol indices) and PERMANOVA, respectively. Taxonomic and functional biomarkers were identified via Linear Discriminant Analysis Effect Size (LEfSe), with LDA scores >1.5 and p < 0.05 considered significant. Mixed factorial ANOVA with repeated measures on time was used to analyze all clinical and questionnaire outcomes. Post hoc testing was performed using Sidak correction. Independent t-tests were used for between-group delta comparisons, with effect sizes reported using Cohen’s d (thresholds: small > 0.2, medium > 0.5, large > 0.8). A significance level of p < 0.05 was applied across analyses.

[0313] 4.4.2 - Results: Microbiome Structure and Composition

[0314] Alpha diversity indices (Shannon and Chaol) did not differ significantly between groups over time, though a time effect was observed for Shannon diversity (p = 0.03), independent of treatment. Beta diversity (community heterogeneity) revealed clustering by timepoint and treatment group; however, PERMANOVA results indicated no significant treatment effects at either baseline (p = 0.105) or postintervention (p = 0.119). Donor-specific microbiome signatures accounted for approximately 91% of the total variance in beta diversity, necessitating within-group comparisons for downstream taxonomic analyses.

[0315] LEfSe analysis identified four significantly enriched taxa in the Comparative Formulation group post-intervention: Lactobacillus acidophilus. Bifidobacterium bifidum. Lactococcus lactis CH LC01, and Acetatifactor sp900066565 ASM1486575vl. One taxon (Clostridium sp000435835) was diminished. In contrast, six taxa were enriched and five were diminished in the Placebo Formulation group, suggesting the Comparative Formulation exerted a more targeted modulation of gut microbial communities.

[0316] 4.4.2 - Results: Microbial Functional Pathways Functional metagenomic predictions revealed that the Comparative Formulation enriched two key metabolic pathways: palmitate biosynthesis (PWY_5994) and guanosine ribonucleotide biosynthesis (PWY 7221). No pathways were significantly downregulated. The Placebo Formulation group exhibited enrichment of six pathway s but reductions in five others, indicating less stable functional modulation.

[0317] 4.4.2 - Results: Gastrointestinal Outcomes

[0318] There were no statistically significant changes in stool consistency (p = 0.634) or bowel frequency (p = 0.157) between groups over time. The Bristol Stool Scale showed a non-significant trend favoring the Comparative Formulation at baseline (p = 0.090, d = 0.53). but change scores postintervention were similar. A trend (p = 0.058, d = 0.73) indicated a 62.5% improvement in DQLQ scores among the Comparative Formulation users, whereas Placebo users experienced a 50% worsening in scores. Although not statistically significant, this effect size suggests a clinically meaningful improvement in digestive quality of life with supplementation with the Comparative Fonnulation.

[0319] 4.4.2 - Results: Clinical Safety and Biomarkers

[0320] Supplementation with the Comparative Formulation was well tolerated and exhibited no negative effects on CBC. CMP, lipid profiles, blood pressure, or anthropometric measures. Notably, significant changes in creatinine (+6.7%) and estimated glomerular filtration rate (eGFR; -5.6%) were observed in the Placebo Formulation group only, suggesting that the Comparative Formulation had no detrimental effects on renal function. No adverse events were reported in the Comparative Formulation group other than one case of mild bloating; a comparable frequency of AEs (6.7%) was reported in the Placebo Formulation group (abdominal pain and diarrhea)

[0321] 4.4.2 -Conclusion

[0322] In summary, supplementation with the Comparative Formulation over a 4-week period in healthy adults resulted in selective enrichment of beneficial probiotic taxa and functional microbial pathways without disrupting overall microbial diversity. The product was safe, well-tolerated, and showed a promising trend toward improved digestive quality of life.

[0323] 4.5 - Example 5 - In Vivo Studies on the Gut Health and Nutritional Gaps in Healthy Adults with Occasional Gastrointestinal Issues using the Test Formulation

[0324] 4.4.1 - Objective and Methods This study was conducted to evaluate the effects of short-term daily supplementation with the Test Formulation on several indicators of gut health in adults reporting occasional digestive symptoms, compared to a Placebo Formulation. The primary objective was to assess changes in fecal metabolomic profiles and microbe -derived metabolites. This approach allows for a better understanding of how the Test Fonnulation may influence metabolic activity related to digestion, nutrient absorption, microbial function, inflammation, etc.

[0325] In addition to the metabolomic analysis, a portion of each stool sample was preserved for potential future metagenomic sequencing. Together, these microbiome assessment methods offer a more complete view of the gut environment and how it may shift in response to the Test Formulation.

[0326] Secondarily, the study examined whether the Test Formulation helped fill common dietary nutrient gaps, using data from 24-hour dietary recalls. The study also tracked changes in GI symptom severity and digestion-related quality of life across the intervention.

[0327] Forty adults between the ages of 18 and 59 were enrolled. All participants reported experiencing occasional digestive symptoms (e.g., bloating, abdominal discomfort, reflux, or irregularity) but were otherwise healthy. Eligibility’ required maintaining their normal diet and lifestyle, and participants were asked to refrain from introducing new supplements, medications, or therapies that could affect gut health during the study.

[0328] Individuals were excluded during the screening process for: antibiotic use, diagnosed gastrointestinal or metabolic diseases, food allergies or intolerances, or extreme dietary patterns (e.g., keto, vegan, or carnivore).

[0329] This was a randomized, double-blind, crossover study conducted virtually. Each participant completed two 2-weck intervention phases: one with the Test Fonnulation and one with a taste matched Placebo Formulation. Intervention phases were separated by a 2-w cek w ashout period.

[0330] At each phase (baseline, midpoint, and endpoint), participants completed a set of validated questionnaires, recorded their weight, and collected a stool sample from home using a standardized kit. Instructions and consent materials were provided in advance, and the protocol was designed to be low- burden while capturing a broad spectrum of relevant data.

[0331] 4.4.2 - Nutrient Gaps Participants completed a 24-hour dietary intake assessment at the start and end of each 14-day supplementation period using the Automated Self-Administered 24-Hour Dietary Assessment Tool (ASA24®). Nutrient gaps were defined as the difference between an individual's reported dietan intake and established dietary targets [the Estimated Average Requirements (EARs) for specific nutrients]. Sixteen micronutrients were included in the assessment based on the following criteria: the micronutrients were present in the Test Fonnulation, could be measured by ASA24®. and had an EAR. Tire combined nutrient gap score was determined by adding the nutrient intakes that met the EAR, with each nutrient meeting the EAR counting as 1, for a total maximum score of 16. Nutrient values from the Test Formulation or Placebo Fonnulation were added to the respective diets, and a nutrient gap score was computed to determine the impact of each treatment. Data were analyzed using 2-way analysis of variance and Fishers’s LSD test for multiple comparisons.

[0332] 4.4.3 - Gastrointestinal Tolerability

[0333] The Gastrointestinal Symptom Rating Scale (GSRS) is a validated questionnaire used to assess the severity and frequency of common gastrointestinal symptoms, such as bloating, abdominal pain, reflux, and indigestion. The questionnaire is organized into two sections, both including four to seven questions. Section 1 addresses upper abdominal issues (reflux, heartbum, bloating, cramps, vomiting, and nausea) and Section 2 addresses lower abdominal issues (intestinal cramps, flatulence, urge to defecate, left abdominal pain, right abdominal pain, loose stool, and diarrhea). Each participant completed the 13 items on a 10-point scale ranging from 0 (no problem at all) to 9 (the worst it has ever been). The Digestion-associated Quality of Life Questionnaire (DQLQ) is a validated tool used to evaluate how digestive symptoms impact an individual’s daily functioning and overall quality of life and was provided to participants before and after each intervention period.

[0334] 4.4.4 - Stool Sample Collection and DNA Extraction

[0335] A total of 79 stool samples were collected from study participants across baseline and endpoint visits. Samples were frozen immediately at -80 °C to preserve microbial DNA integrity. DNA was extracted using the ZymoBIOMICS DNA / RNA Miniprep Kit according to the manufacturer’s protocol. Extracted DNA was eluted in 50 pL of nuclease-free water and quantified using a Qubit 4 Fluorometer with a double -stranded DNA high-sensitivity assay.

[0336] 4.4.5 - Metagenomic Library Preparation and Sequencing

[0337] Metagenomic sequencing libraries were prepared using the Nextera XT DNA Library Preparation Kit. Library quality and fragment size distributions were confinned using an Agilent 2100 Bioanalyzer with the DNA High Sensitivity Kit. Equimolar concentrations of each library were pooled and purified by gel electrophoresis followed by extraction using the Qiagen QIAquick Gel Extraction Kit. Pooled libraries were sequenced on an Element AVITI instrument generating paired-end reads of 150 base pairs in length (2 x 150 bp).

[0338] 4.4.6 - Quality Control and Taxonomic Annotation

[0339] Sequence quality was evaluated using FastQC. Reads were filtered and trimmed using fastp with a minimum Phred quality score of 28 and a minimum read length of 90 base pairs. Human-derived sequences were excluded to avoid host contamination. Taxonomic profiling was perfonned using Kraken2 against a custom reference database that included bacteria and fungi. A species-level annotation table was generated for downstream analysis.

[0340] 4.4.7 - Functional Gene Annotation

[0341] Non-human reads were dereplicated using VSEARCH, then analyzed using eggNOG-mapper v2.0 with the cggNOG 5.0 database for functional annotation. KEGG orthologs were identified and linked to corresponding read abundances to generate a quantitative table of microbial gene content.

[0342] 4.4.8 - Alpha and Beta Diversity Analyses

[0343] Alpha diversity metrics (species richness and Pielou’s evenness) were calculated at multiple subsampling depths and averaged across 20 iterations to ensure robustness. Diversity between samples (beta diversity) was computed using Bray-Curtis dissimilarity and visualized using Principal Coordinates Analysis (PCoA). Multivariate analyses were also performed using Partial Least Squares Discriminant Analysis (PLS-DA) to assess compositional shifts between experimental groups.

[0344] 4.4.9 - Statistical and Biomarker Analysis

[0345] Tire primary statistical analyses for dietary analyses included repeated-measures ANOVA and independent t-tests to evaluate changes over time and between conditions, with significance set at p < 0.05 and trends noted for p-values between 0.051 and 0.10. To evaluate the microbiome parameters, PERMANOVA was applied to beta diversity matrices, and Wilcoxon Signed-Rank Tests were used for pairwise comparisons. Biomarker discovery was performed using LEfSe to identify differentially abundant taxa and KEGG genes, using thresholds of p < 0.05 and log LDA score > 1.0 for taxa and > 0.25 for genes. Only features exceeding a minimum abundance threshold were retained for interpretation.

[0346] 4.4.10 - Results Summary Primary outcomes included how supplementation with the Test Formulation fdled micronutrient gaps, GI tolerability, microbiome effects, and safety.

[0347] • The Test Formulation closed nutrient gaps by fulfilling significantly more nutrient requirements.

[0348] • The Test Formulation enriched healthy probiotic bacteria species in the gut after 2 weeks of supplementation [8 taxa (or 3 beneficial species) were significantly increased following Test Formulation consumption.

[0349] • Gut microbiome benefits were lost when supplementation with the Test Formulation was stopped.

[0350] • The Test Formulation had good GI tolerability.

[0351] • No significant differences in digestion from placebo after 14 days of supplementation with the Test Formulation.

[0352] 4.4.11 - Results: Nutrient Gaps

[0353] Of the 40 participants, 23 (43 ± 8 years and 87.0% F) completed at least one dietary recall for the Test Formulation and placebo conditions and were included in the nutrient gap analysis. After the interventional nutrient values were added to the recalls, the Test Formulation and Placebo Fonnulation groups met 14.8 ± 1.3 and 11.7 ± 3.3 out of 16 nutrient EARs, respectively. Tire mean difference forthe number of nutrient requirements met between conditions was 3.1 ± 3.4 (P = 0.0003). Vitamins C and E were the most common nutrient requirements met in the Test Formulation group compared to the placebo group.

[0354] 4.4.12 - Results: Microbiome

[0355] No significant differences were detected in the number of observed species or Pielou's Evenness between the two treatment groups. There were no significant differences in overall community composition as indicated by PERMANOVA analysis (p > 0.05). Despite this, there was clear clustering between the treatment groups at each time point using PLS-DA ordination. LEfSe analysis revealed that supplementation with the Test Formulation led to significant (LDA > 0.25, p < 0.05) enrichment of 8 taxa including Bifidobacterium animalis, and Lacticaseibacillus casei, and Lactiplantibacillus acidophilus. Additionally, the enrichment of these taxa caused various KEGG orthologs associated with microbial growth and nutrient utilization to have greater representation within the microbiome implying potential metabolic benefits that could be conferred to the host. Further, in a subset of participants (n = 15) wash- out analysis revealed these benefits were lost with an observed significant decrease (p < 0.05) in 19 taxa and 73 functional differences.

[0356] 4.4.13 - Results: GI Tolerability

[0357] During the Test Formulation phase, participants experienced a 22.20% reduction in the mean GSRS score, compared to a 19.82% reduction during the placebo phase, where a reduction in score is indicative of an improvement in the severity of symptoms. The most notable changes were reductions in reflux score by 34.32% with the Test Formulation and in indigestion (24.32%) with the Placebo Formulation. However, the changes in total GSRS score and GSRS subscores from Baseline, when compared between the two groups, were not statistically significant.

[0358] The DQLQ was used as a measure of the impact of digestive symptoms on participants' quality of life. In the Test Formulation phase, participants experienced a reduction of 37.11% in the mean DQLQ score from Baseline to Endline, indicative of an improvement. However, in the placebo phase, there was a similar reduction of 42.99%. There was no statistically significant difference between the two groups.

[0359] 4.5 - Example 5 - In Vivo Studies on the Gut Health and Nutritional Gaps in Highly Active Adults using the Test Formulation

[0360] 4.5.1 - Objective and methods

[0361] This randomized, double-blind, placebo-controlled crossover study was designed to examine the effects of short-term supplementation with the Test Formulation on gut health and nutritional status in resistance-trained men and women. The primary objective was to assess how a 14-day supplementation period impacted feeal metabolite profiles, providing insights into the metabolic activity of gut microbes, nutrient metabolism, inflammation, and other indicators of gastrointestinal function.

[0362] A secondary aim was to explore whether the Test Formulation helped fill common micronutrient gaps and whether it influenced self-reported digestive symptoms.

[0363] Twenty healthy, resistance-trained adults between the ages of 18 and 35 participated in the study. Each participant completed two 14-day supplementation phases (one with the Test Formulation and one with a Placebo Formulation), separated by atwo-week washout period. Stool samples were collected before and after each phase for metabolomic analysis. Participants consumed their assigned treatment once daily, mixing the powder with water. Throughout the study, participants were instructed to maintain their usual diet and training routines. They completed 24-hour dietary recalls using the ASA-24 tool and reported digestive symptoms using the Digestion-associated Quality of Life Questionnaire (DQLQ).

[0364] Anthropometric and cardiovascular measures were collected at baseline. Adverse events were monitored throughout the study period.

[0365] 4.5.2 - Nutrient Gaps

[0366] Participants completed a 24-hour die tan intake assessment at the start and end of each 14-day supplementation period using the Automated Sclf-Administcrcd 24-Hour Dietary Assessment Tool (ASA24®). Nutrient gaps were defined as the difference between an individual's reported dietary intake and established dietary targets [the Estimated Average Requirements (EARs) for specific nutrients]. Sixteen micronutrients were included in the assessment based on the following criteria: the micronutrients were present in the Test Formulation, could be measured by ASA24®, and had an EAR. The combined nutrient gap score was determined by adding the nutrient intakes that met the EAR, with each nutrient meeting the EAR counting as 1, for a total maximum score of 16. Nutrient values from the Test Formulation or Placebo Formulation were added to the respective diets, and a nutrient gap score was computed to detennine the impact of each treatment. Data were analyzed using 2-way analysis of variance and Fishers’s LSD test for multiple comparisons.

[0367] 4.5.3 - Gastrointestinal Tolerability and Adverse Event Monitoring

[0368] The Digestion-associated Quality of Life Questionnaire (DQLQ) is a validated tool used to evaluate how digestive symptoms impact an individual’s daily functioning and overall quality of life and was provided to participants before and after each 2-week intervention period. Adverse events were also monitored throughout the study.

[0369] 4.5.4 - Stool Sample Collection and DNA Extraction

[0370] A total of 79 stool samples were collected from study participants across baseline and endpoint visits. Samples were frozen immediately at -80°C to preserve microbial DNA integrity. DNA was extracted using the ZymoBIOMICS DNA / RNA Miniprep Kit according to the manufacturer’s protocol. Extracted DNA was eluted in 50 pL of nuclease-free water and quantified using a Qubit 4 Fluorometer with a double -stranded DNA high-sensitivity assay. 4.5.5 - Metagenomic Library Preparation and Sequencing

[0371] Metagenomic sequencing libraries were prepared using the Nextera XT DNA Library Preparation Kit. Library quality and fragment size distributions were confirmed using an Agilent 2100 Bioanalyzer with the DNA High Sensitivity Kit. Equimolar concentrations of each library were pooled and purified by gel electrophoresis followed by extraction using the Qiagen QIAquick Gel Extraction Kit. Pooled libraries were sequenced on an Element AVITI instrument generating paired-end reads of 150 base pairs in length (2 x 150 bp).

[0372] 4.5.6 - Quality Control and Taxonomic Annotation

[0373] Sequence quality was evaluated using FastQC. Reads were filtered and trimmed using fastp with a minimum Phred quality score of 28 and a minimum read length of 90 base pairs. Human-derived sequences were excluded to avoid host contamination. Taxonomic profiling was performed using Kraken2 against a custom reference database that included bacteria and fungi. A species-level annotation table was generated for downstream analysis.

[0374] 4.5.7 - Functional Gene Annotation

[0375] Non-human reads were dereplicated using VSEARCH, then analyzed using eggNOG-mapper v2.0 with the eggNOG 5.0 database for functional annotation. KEGG orthologs were identified and linked to corresponding read abundances to generate a quantitative table of microbial gene content.

[0376] 4.5.8 - Alpha and Beta Diversity Analyses

[0377] Alpha diversity metrics (species richness and Pielou’s evenness) were calculated at multiple subsampling depths and averaged across 20 iterations to ensure robustness. Diversity between samples (beta diversity) was computed using Bray-Curtis dissimilarity and visualized using Principal Coordinates Analysis (PCoA). Multivariate analyses were also performed using Partial Least Squares Discriminant Analysis (PLS-DA) to assess compositional shifts between experimental groups.

[0378] 4.5.9 - Statistical and Biomarker Analysis

[0379] Tire primary statistical analyses for dietary' analyses included repeated-measures ANOVA and independent t-tests to evaluate changes over time and between conditions, with significance set at p < 0.05 and trends noted for p-values between 0.051 and 0.10. To evaluate the microbiome parameters, PERMANOVA was applied to beta diversity matrices, and Wilcoxon Signed-Rank Tests were used for pairwise comparisons. Biomarker discovery was performed using LEfSe to identify differentially abundant taxa and KEGG genes, using thresholds of p < 0.05 and log LDA score > 1.0 for taxa and > 0.25 for genes. Only features exceeding a minimum abundance threshold were retained for interpretation

[0380] 4.5.10 - Results

[0381] Primary outcomes included how supplementation with the Test Formulation filled micronutrient gaps, microbiome effects, and safety.

[0382] 4.5.10.1 - Results: Micronutrient Gaps

[0383] All 20 participants completed baseline and endpoint recalls and were included in the nutrient gap analysis. At baseline, the Test Fonnulation and Placebo Formulation groups met 13.9 ± 2.5 and 12.8 ± 2.8 out of 16 nutrient EARs, respectively with no significant difference between groups (p > 0.05). Following the intervention, the Test Formulation group significantly increased the total number of EARs met compared to the Placebo Formulation group [2.8 (95% CI: 1.1, 4.4); p = 0.0011], Within the Test Formulation group, 1.4 (95% CI: 0.3, 2.5) nutrient gaps were closed on average compared to -0.2 (95% CI: -1.3. 0.9) in the placebo group. Vitamins A, C, and E were the most common nutrient gaps filled by supplementation with the Test Formulation.

[0384] 4.5.10.2 - Results: Questionnaire

[0385] There were no significant differences in the DQLQ outcomes between the Test Formulation and placebo intervention period indicating that the Test Formulation had good tolerability in highly active adults. There were no adverse events reported for either intervention.

[0386] 4.5.10.3 - Results: Microbiome

[0387] Sequencing Output All 79 samples yielded high-quality sequencing data with a minimum of 1.5 million reads per sample. The average sequencing depth was 8.24 million reads, ranging from 4.47 to 12.64 million reads per sample post-filtering, resulting in a total of over 651 million sequences across the study.

[0388] 4.5.10.4 - Results: Microbial Community Structure - Alpha Diversity

[0389] No statistically significant differences were observed in species richness or evenness across treatment groups or timepoints (p > 0.05). This is consistent with expectations for nutritional interventions in generally healthy individuals, where broad shifts in microbial alpha diversity are not anticipated.

[0390] 4.5.10.5 - Results: Microbial Community Structure - Beta Diversity

[0391] PCoA plots based on Bray-Curtis dissimilarity revealed modest clustering trends by treatment group; however, no statistically significant differences in global community composition were detected (PERMANOVA, p > 0.05). PLS-DA analyses indicated greater variability and distinct clustering between pre- and post-Test Fonnulation supplementation samples relative to Placebo Formulation, suggesting that the Test Fonnulation may elicit individual-specific shifts in community composition not captured by global tests.

[0392] 4.5.10.6 - Results: Taxonomic Biomarker Discovery

[0393] LEfSe analysis identified six bacterial taxa significantly enriched following supplementation with the Test Formulation. These included two genera — Lacticaseibacillus and Lactiplantibacillus — and four species: Lacticaseibacillus casei, Lacticaseibacillus rhamnosus, Lactiplantibacillus plantarum, and Bifidobacterium animalis. All six taxa met statistical thresholds and biological relevance criteria (LDA > 1.0, p < 0.05). with no such enrichment observed in the placebo arm.

[0394] 4.5.10.7 - Results: Post-Treatment Washout Effects

[0395] In participants who received the Test Formulation prior to placebo, a follow-up analysis assessed microbiome changes after the 2-week washout period. PLS-DA revealed distinct clustering between postTest Formulation and post-washout samples. Eleven taxa were significantly reduced post-washout, including families Christensenellaceae and Eubacteriaceae; genera Christensenella, Gordonibacter, Eubacterium, and Lacticaseibacillus; and species Christensenella minuta, Eubacterium limosum, Blautia obeum, Bifidobacterium animalis, and L. rhamnosus.

[0396] 4.5.10.8 - Results: Functional Gene Analysis - Alpha and Beta Diversity of Functional Genes

[0397] The richness and evenness of KEGG genes remained stable across all conditions (p > 0.05). Similarly, PCoA did not show significant global shifts in functional gene composition (PERMANOVA, p > 0.05). Nonetheless, PLS-DA visualizations again suggested greater treatment-related variability postTest Fonnulation supplementation. 4.5.10.9 - Results: Enrichment of KEGG Pathways

[0398] Functional pathway analysis of genes associated with the six enriched taxa revealed increased representation in pathways supporting: Ribosomal function, ABC transporters, Glycolysis and carbohydrate metabolism. Amino sugar metabolism, and Quorum sensing.

[0399] 4.5.10.10 - Results: KEGG Biomarker Discovery

[0400] LEfSe identified 294 KEGG orthologs enriched exclusively in the Test Formulation-treated group. Of these, 288 were aligned with B. animalis, suggesting a strong taxon-specific functional enrichment. The top 10 KEGG pathways accounted for 107 of these gene annotations and were related to nutrient transport, metabolism, and bacterial proliferation.

[0401] 4.5.10.11 - Results: Post-Washout Gene Reduction

[0402] In post-washout comparisons, eight KEGG orthologs were significantly reduced, including four associated with B. animalis, indicating a decline in functional potential upon discontinuation of the Test Formulation.

[0403] 4.5.10.12 - Results: Metabolite Predictions

[0404] No distinct metabolite predictions were derived from the gene profiles due to sequence noise and lack of transcript-level resolution. This highlights the need for future studies incorporating metabolomics or transcriptomics to capture dynamic biological activity.

[0405] 4.5.11 - Conclusions

[0406] Consumption of the Test Formulation significantly improved nutrient adequacy by reducing nutrient gaps in healthy resistance-trained adults. Additionally, Test Fonnulation supplementation significantly improved the abundance of beneficial taxa and community function of the gut microbiome in highly active males and females. Further, in a subset of participants, wash-out analysis revealed these benefits were lost with an observed significant decrease in 1 1 taxa.

[0407] 4.6 - Comparison of the Test Formulation and Comparative Formulation Human Clinical Trials A comparative evaluation of the Test Formulation and the Comparative Formulation demonstrates that the Test Formulation is a scientifically and clinically enhanced formulation based on improvements in composition and validated outcomes across multiple human clinical investigations.

[0408] The Test Formulation includes five probiotic strains compared to the two strains included in the Comparative Formulation (each of the five probiotic strains of the Test Formulation differ from the two of the Comparative Formulation). This compositional enhancement resulted in more robust and reproducible effects on the gut microbiome across all clinical studies. Whereas the Comparative Formulation was shown to enrich four beneficial taxa and two functional microbial pathways, the Test Formulation produced statistically significant enrichment of six to ten health-promoting bacterial species, including Bifidobacterium animalis, Lacticaseibacillus rhamnosus, Lactobacillus acidophilus. Lacticaseibacillus casei. and Lactiplantibacillus plantarum. Functional metagenomic analyses revealed the Test Formulation led to the enrichment of over 290 KEGG orthologs, primarily associated with nutrient metabolism, cellular growth, and microbial signaling. These functional changes were not observed in the Comparative Formulation study. Importantly, these effects were reversed during washout phases, indicating a dose -responsive and biologically active intervention with the Test Formulation.

[0409] Tire Test Formulation includes increased quantities of vitamin C, zinc, magnesium, vitamin K2, and vitamin Bl 2, as well as the addition of bioactive forms of vitamin Bl (benfotiamine) and vitamin B6 (pyridoxal-5-phosphate, or P5P). These changes were directly associated with improved nutrient bioavailability and systemic nutritional status. In a controlled pharmacokinetic study, the Test Formulation consumption led to significantly greater postprandial area under the curve (AUCo-t) and peak plasma concentrations (Cmax) for multiple nutrients, including vitamin C, folate, zinc, thiamin, riboflavin, biotin, and nicotinamide. Furthermore, a 12-week randomized controlled trial demonstrated significant improvements in circulating vitamin C (+33%), serum folate (+26%), red blood cell folate (+6%), and a 10% reduction in plasma homocysteine concentrations, all of which were not observed with the Comparative Formulation. The inclusion of benfotiamine and P5P in tire Test Formulation provides a mechanistic rationale for these improvements, as both cofactors are critical in homocysteine metabolism via the transsulfuration and methylation pathways.

[0410] In terms of addressing dietary inadequacy, the Test Formulation demonstrated a statistically significant improvement in micronutrient adequacy in all studies in which nutrient gaps were measured. Across four separate trials, the Test Formulation supplementation resulted in significantly reduced dietary' inadequacy for several micronutrients. Vitamins A, C, and E were among the most commonly improved. By contrast, the Comparative Fonnulation did not produce statistically significant improvements in nutrient gap closure or biomarker-based assessments of nutrient status during its 30-day intervention.

[0411] These findings provide robust evidence that the Test Formulation delivers greater nutritional sufficiency and systemic nutrient exposure, confirming that the enhanced formulation produces functionally superior outcomes.

[0412] Both the Comparative Formulation and the Test Formulation were found to be safe and well tolerated. However, the Test Formulation was evaluated in more varied populations, across longer durations, and under more stringent monitoring, with no adverse events or safety concerns reported. Gastrointestinal tolerability remained high, and no negative effects were observed on liver enzymes, clinical chemistry, or self-reported gastrointestinal function.

[0413] In summary', the Test Formulation represents a clinically and functionally superior formulation relative to the Comparative Formulation. Through the inclusion of additional probiotic strains, increased and bioactive micronutrient content, and validation across multiple, rigorously designed clinical studies, the Test Formulation has demonstrated enhanced microbiome modulation, greater bioavailability, improved nutrient status, and significant reductions in homocysteine levels.

[0414] While the invention has been disclosed in some detail by way of illustration and example for purposes of clarity of understanding, it is apparent to those in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. Therefore, the description and examples should not be construed as limiting the scope of the invention.

[0415] All references, publications, patents, and patent applications disclosed herein are hereby incorporated by reference in their entirety.

Claims

What is Claimed is:

1. A composition comprising: one or more of each of adaptogens, botanicals, seaweeds, enzymes, extracts, fibers, microalgae, micronutrients, minerals, protein, vitamins, and whole fruit or vegetable powders; and three or more of probiotics.

2. Tire composition of claim 1, comprising: one or more of each of seaweeds, enzymes, and proteins; two or more of microalgae; three or more of each of probiotics and fibers; four or more of each of botanicals, micronutrients, and whole fruit or vegetable powders; seven or more of adaptogens; twelve or more of each of extracts and minerals; and fourteen or more vitamins.

3. The composition of claim 1 or 2, further comprising a nutraceutically acceptable carrier.

4. The composition of claim 3, comprising benfotiamine.

5. The composition of claim 3. comprising myo-inositol.

6. The composition of claim 3, comprising sophora japonica extract.

7. The composition of claim 3. comprising cocoa extract.

8. The composition of claim 3, comprising four probiotics.

9. The composition of claim 3. comprising five probiotics.

10. The composition of claim 3, comprising sophora japonica extract, cocoa extract, and four probiotics.

11. The composition of claim 3, comprising sophora japonica extract, cocoa extract, and five probiotics.

12. The composition of claim 3. wherein the adaptogen is Licorice plant, Reishi Mushroom, Shiitake Mushroom, Ashwagandha, Astragalus, Ginseng, Rhodiola rosea, or combinations thereof.

13. Tire composition of claim 3, wherein the botanicals are Wheat Grass, Ginger, Slippen' Elm, Green tea powder, or combinations thereof.

14. The composition of claim 3, wherein the seaweed is Fucus vesiculosus.

15. The composition of claim 3. wherein the extracts are Citrus Bioflavonoids, Rosehip Fruit extract, Artichoke extract. Sophora japonica extract. Rosemary Leaf extract. Cocoa seed extract, Wolfberry fruit extract. Dandelion extract. Burdock Root extract. Hawthorn berry extract, Bilberry extract. Milk Thistle Seed extract, Grape Seed Extract, Pine bark extract, Black currant extract, Japanese knotweed, or combinations thereof.

16. The composition of claim 3. wherein the fiber is fruit fiber, chickory root, beta glucans, or combinations thereof.

17. The composition of claim 3. wherein the microalgae is Spirulina, Chlorella, or combinations thereof.

18. Tire composition of claim 3, wherein the micronutrient is choline, inositol, alpha lipoic acid, coenzyme Q10, or combinations thereof.

19. The composition of claim 3, wherein the mineral is calcium, potassium, magnesium, zinc, colloidal silica, selenium, manganese, boron, molybdenum, copper, chromium, or combinations thereof.

20. The composition of claim 3. wherein the probiotic is Lcicticaselbaclllus rhamnosus GG. Lacticaseibacillus casei LC-11, Lactobacillus acidophilus NCFM, Bifidobacterium lactis HN019. I jactiplantibacilhis plantarum LP-1 15, or combinations thereof.

21. The composition of claim 3. wherein the protein is Pea Protein.

22. The composition of claim 3, wherein the vitamin is Vitamin C, Vitamin E, Vitamin K2, Vitamin Bl, Vitamin B6, Vitamin B3, Vitamin B5, Vitamin Bl, Vitamin B2, Vitamin A, Vitamin B9, Vitamin B12, Vitamin B7, or combinations thereof.

23. The composition of claim 3, wherein the whole fruit or vegetable powder is Papaya, Acerola Cherry. Pineapple, Cocoa Bean, Alfalfa Leaf, Barley leaf, Carrot, Broccoli, Beetroot, or combinations thereof.

24. A method for improving gut health, for enhancing energy, for improving focus, for reducing cravings, for improving stress management, for improving health, for promoting healthy aging, for replenishing nutrients, for supporting immune health, for promoting skin health, for promoting hair and nail growth, and for enhancing recovery after physical activity in a subject in need thereof, the method comprising administering an effective amount of a composition of claim 1 or 2.

25. A food, food product, food additive, or dietary supplement comprising a composition of claim 1 or 2.

26. A kit comprising the composition of claim 1 or 2.